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 Mesenchymal stem cells (MSCs), a type of “adult” stem cell found in most organs, represent an 
emerging tool in the field of regenerative medicine. In the setting of myocardial injury, for example, 
MSCs have been shown to promote repair and recovery. Studies have been hampered, however, by 
variation in MSC phenotypes, as defined by cell surface marker expression, and the absence of a clear 
consensus of what MSC phenotypes are best able to support regeneration. Providing insight into the 
regenerative capabilities of varying MSCs phenotypes is crucial to their continued success in therapies. 
One cell surface marker that has been shown to have functional relevance to regenerative 
medicine is endoglin (CD105). Endoglin is a type I transmembrane protein that functions as an auxiliary 
receptor for the TGFβ receptor complex. The absence of endoglin on MSCs reportedly defines a 
population with a greater propensity for cardiovascular differentiation and greater capacity to support 
myocardial repair. However, despite their ability to improve post-infarct cardiac function and reduce the 
size of resultant scars, the retention of these cells in myocardial tissue varies from only 3%-6%. Thus, 
transdifferentiation seems an unlikely explanation for the regenerative effects. In addition to their 
capacity for multipotential differentiation, MSCs also have a reported ability to suppress various 
immune responses, including suppression of stimulated T-cell proliferation. I hypothesized that the 
absence of CD105 may identify a population of MSCs with an altered capacity to modulate the 
immunologic milieu at the time of myocardial injury, and this difference in immunomodulatory function 
accounts for the improved outcomes. 
 To investigate this idea, MSCs that either express endoglin (CD105+) or not (CD105-) were co-
cultured with T-cells and effects on stimulated T-cell proliferation examined. Surprisingly, neither 
CD105+ nor CD105- MSCs were able to suppress proliferation of either CD4+ or CD8+ T-cells. In light of 
this observation, effects of MSCs on T-cell differentiation were assessed. Notably, co-culture of both 
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CD105+ and CD105- MSCs with CD4+ T-cells showed a striking effect on T-cell differentiation. Syngeneic 
MSCs induced Th2 skewing, with increased expression of IL-4 and IL-10 and a marked decrease in IL-17 
expression. The presence of CD105 in the MSCs influenced this outcome, with a more pronounced 
decrease in IL-17 expression and increased IL-4 secretion. 
Effects of allogeneic MSCs on T-cell differentiation were also examined. Due to the reported 
“immune privilege” of MSCs, it has been proposed that allogeneic MSCs may be utilized to expand the 
pool of MSCs available for clinical use. In an allogeneic co-culture system, both CD105+ and CD105- MSCs 
significantly affected T-cell differentiation. Compared to syngeneic MSCs, allogeneic MSCs stimulated 
higher expression of IL-4, IL-5, and IL-10, as well as increased secretion of IL-4 and IL-10. There were 
fewer differences between CD105+ and CD105- MSCs. However, CD105- MSCs induced much less IL-2 
and IFNγ compared to CD105+ MSCs. These results indicate that MSCs influence T-cell differentiation, 
resulting in a Th2 skewing with increased production of the immunosuppressive cytokine IL-10 and, in 
the case of syngeneic cells, diminished Th17 differentiation. This effect could be essential for the 
previously described MSC-induced cardiac functional preservation, and could explain differences 
between CD105+ and CD105- phenotypes. 
 In addition to these mechanistic studies, I also examined potential clinical relevance of CD105 
expression in MSCs in umbilical cord blood transplantation. This question arose from a clinical study was 
underway at the University of Kansas Cancer Center that focused on using hyperbaric oxygen (HBO) for 
improving clinical outcomes post umbilical cord blood (UCB) transplant. In the observation of post-
transplant transfusion requirements, HBO-treated patients required less supportive blood products than 
historic UCB-recipients. Furthermore, they experienced decreased time to transfusion independence. 
However, upon examining the correlation between levels of erythropoietin in these HBO-patients to 
their transfusion requirements, the data did not match with animal studies, which showed a reduction 
in erythropoietin was the causative method by which HBO improved engraftment. 
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 Therefore, we examined the supportive role of MSCs in response to HBO in the hematopoietic 
niche. This included observing changes in CD105 on MSCs after exposure to HBO, as endoglin is a known 
hypoxia response gene. While the observation of immunomodulatory factors produced by MSCs as a 
result of HBO is still underway, a downregulation of CD105 12 hours after exposure to HBO was 
observed. This correlates to the homing window of hematopoietic stem cells in the context of transplant 
and may be indicative of changes in MSCs providing a more supportive bone marrow microenvironment 
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Chapter 1: Introduction 
 
 Endoglin (CD105) is an elusive, multifaceted protein that plays a critical role in the development 
and functionality of many mesoderm derived tissues.  Initially discovered 30 years ago, the protein has 
gained prominence as a marker of mesenchymal stem cells (MSCs) in the last 15 years. However, there 
is still debate about CD105-expression on MSCs, and its causative role for observed variation in MSC-
performance. In 2007, Kolf et al published a review discussing the inconsistencies of MSC markers and 
lack of a cohesive surface protein profile, evidenced by a survey of 91 original papers investigating MSC 
properties. Of these, 8 listed CD105 as a “marker,” thereby stating its necessity for the identity of a MSC 
in both human and murine lines.1  In recent years, there has been debate as to the presence or absence 
of endoglin distinguishing a unique population of MSCs. Some groups have successfully proven that 
CD105 is a useful marker for differentiation and preservation of cardiac function. 2 Others have 
determined that the lack of endoglin is necessary for achieving optimal immunologic modulation. 3 
There has not been consensus, therefore, about the function of endoglin and how it serves MSCs. The 
purpose of this introduction is to examine the function of endoglin as it has been explored in a variety of 
tissues, determine the consistency of its signaling pathway in those tissues, and extrapolate the function 
of its signaling and the consequences it has in a population of MSCs. 
Protein Structure and Function 
Structure and Variants 
 The protein of endoglin has been identified to subsist in several forms. The predominant variant, 
the long form (L-endoglin), is a 180 kDa homodimeric membrane bound glycoprotein. 4 Unless otherwise 
specified, this review will discuss endoglin as it relates to the L-endoglin form. Its identity as the 
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dominant form is derived from its constitutive presence on endothelial cells.5 The two other forms 
discovered, and less frequently explored are the short, membrane bound form described as having a 
role in tumor development.6 7 8 S-endoglin and L-endoglin vary only by their cytoplasmic tails. The short 
form has seven unique intracytoplasmic residues which alter its function. 9The long form containing 47 
intracytoplasmic residues has been well characterized in its function in several tissues, to be discussed in 
a separate portion of this review. Additionally there exists a soluble form of endoglin, known as S-
endoglin. The structural form of soluble endoglin is considerably smaller than its cytoplasmic bound 
counterparts, at only 65 kDa. Mass spectrometry data has revealed that this variant corresponds with 
the N-terminus of L-endoglin structurally. S-endoglin has been demonstrated to play a role in 
preeclampsia, as a disruptor of vascular modulation in response to TGF during pregnancy.10 While an 
interesting mechanism of action was demonstrated in Venkatesha et al’s paper for this clinical 




Figure 1.1: Structural configurations of L- and S-endoglin. 
(A) Surface expression of Endoglin containing an N-terminal orphan domain and a zona pellucida (ZP) domain 
immediately juxtaposed to the membrane surface. A postsynaptic density 95/Drosophila disk large/zonula 
occludens-1 (PDZ)-binding motif is found to be intracytoplasmic at the C-terminus. (B) Differences in amino acid 
sequences for S-and L-endoglin for the cytoplasmic domain.  Figure adapted from Lopez-Novoa et al and the 
American Journal of Physiology;
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Signaling and TGF Associations 
The structural components of L-endoglin, which correspond to their signaling functionality in the 
TGF family, have been well characterized.  Koleva et al in their 2006 paper characterize the 
phosphorylation sites of endoglin as a TGFtype III receptor and the physiologic consequences of the 
intracytoplasmic serine and threonine phosphorylation, accomplished by TBRII and the TGF type I 
receptor family. 12 This family includes activin-like kinase 1 (ALK1) and TBRI (sometimes known as ALK5). 
Previous literature has demonstrated that TGF ligand binding on the TGFRII receptor permits the 
interaction between the TGF type 1 receptor family and TBRII. The latter activates the kinase activities 
of ALK1 and ALK5. These kinases have been characterized to propagate Smad signaling for the effects of 
TGF. This work is based on documented evidence which highlights that endoglin is also a substrate for 
ALK5 and TBRII, and that phosphorylated endoglin is the result of this interaction.13 Notably Koleva et 
al’s studies made use of constitutively active forms of ALK1 (caALK1) and ALK5 (caALK5) in order to study 
their phosphorylation function on their substrate, endoglin.  Using primarily mass spectroscopy data for 
their analysis, this group proved that caALK1 is the direct kinase substrate which phosphorylated 
endoglin on its intracytoplasmic threonine residues. They also provide evidence that the carboxyl 
terminal PDZ-liganding motif regulates this phosphorylation. This kinase action on the threonine 
residues of endoglin allows this group to conclude that the association of endoglin with TBRII is 
necessary prior to its phosphorylation via caALK1. The group discusses their results with an inclination 
stating that the association of the TGFtype I and TBRII receptors with endoglin is a way in which TGF 
modulates the cell in a Smad-independent function. These findings correspond with the hypotheses 
tested by other groups, which state that endoglin alone cannot bind TGF1 and TGF3 without TBRII.14 
This group also finds that endoglin can bind to and associate with the kinase complexes signaled by 
activin-a, BMP2 and BMP 7 – but can only bind these ligands in the presence of their corresponding 
receptors. It has been demonstrated by Barbara et al that endoglin interacts with activin-a and BMP7 via 
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activin type II receptors (ActRII and ActRIIB), and that BMP2 associates with endoglin in the presence of 
ALK3 and ALK6. These functions, as they have been described in several papers, are necessary for 
migration, cell structural integrity and cell to cell adhesion. 15-17 
 
 
Figure 1.2: Hypothetical model of endoglin functionality  
L-Endoglin binds to TGF-β1, TGF-β2, activin, BMP-2, and BMP-7 via its association with TGF-β type II receptors (ActRII, ActRIIB, 
ALK1, ALK2, ALK3, ALK5, ALK6, BMPRII, and TβRII). Sp1 modulates Endoglin transcription through other factors in a hypoxic 
environment. TGF-β1 and β3 propagate intracellular Smads 1/5, 2/3, and 4 by way of the TGF-β receptor complex. Smad6 and 7 
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block the effects of Smad 1/5 and Smad 2/3, respectively. TGF-β signaling through Endoglin inhibits apoptosis by prohibiting the 
function of caspases 3 and 8. Interaction between Zyxin, ZRP-1, Tctex2b, and endoglin alters migration and cell adhesion. 
CD105/TGFbRII complexes are internalized by endocytosis in the presence of thrombin. This figure was adapted from the work 
of Valluru et al
18
 from their publication in Frontiers in Physiology and did not require permission as it is derived from an open-
access article distributed under the Creative Commons Attribution Non Commercial License. 
 
Cytoskeletal Modifications 
 The cytoplasmic domain of endoglin, serving as a substrate as described above, has been shown 
to interact with one protein highly associated with actin assembly, zyxin-related protein I (ZRP-1). This 
protein has been found at focal adhesion sites.19 Sanz-Rodriguez et al determined via proteinalysis that 
the LIM domain of the ZRP-1 protein interacted with the cytoplasmic domain of endoglin, which they 
confirmed using transgenic myoblasts in vivo. In cells that did not express endoglin, ZRP-1 maintained its 
position at focal adhesion points on the cytoskeleton. However, upon the induction of the expression of 
endoglin, ZRP1 moved to associate throughout the cells along fibrillar structures, reminiscent of stress 
fibers. They also conducted a comparative study to determine the role of endoglin’s presence in actin 
organization. Those cells made to express endoglin had parallel actin fibers constructing a concentric 
array which left the center of the cell free of fibers – reminiscent of the actin structure of endothelial 
cells. The cells which did not contain endoglin had F-actin localized in peripheral bands and dense 
bundles at cell-substrate contacts. One of the most important assays from this paper demonstrated that 
when endoglin is engaged (via monoclonal anti-endoglin antibodies); it appears in aggregates at the cell 
surface, bringing the actin skeleton along with it. While this shows interactions anchoring endoglin in the 
cytoskeleton, it also demonstrated the importance of endoglin as a molecule dictating a cell’s structural 
integrity.  




 It therefore comes as no surprise that endoglin is a necessary component for development. In 
models of Hereditary Hemorrhagic Telangiectasia type I, the knocking out of endoglin results in 
embryonic lethality.20 Jonker et al describe the course of endoglin during embryogenesis as it relates to 
murine development.21 This paper provides exquisite detail of the global expression of endoglin during 
development. Making gratuitous use of a LacZ controlled -galactosidase from a reporter cassette 
downstream of endoglin, this team observed crucial findings for where endoglin is first seen. Endoglin 
makes its debut at post-coital day (PCD) 6.5 in mice, in the amniotic fold and developing allantois. In 
mice, these tissues rapidly develop and by PCD 7 endoglin can be seen in the amnion. Not 12 hours 
later, endoglin is found prominently in the cardiogenic plate. As early organogenesis ensues, endoglin 
can be found in areas where vascular development is crucial. Most notably, this group found that 
endoglin was most prominent in the developing endocardium as opposed to the myocardium. They 
offered no evidence or speculation as to the functionality of its presence. With the entirety of the 
circulatory system involving and depending upon the functionality of endoglin, it is no surprise that it is 
crucial for proper vascular development. 
 
Neural Crest Associations 
 The presence of endoglin has been noticed in the importance of neural crest cell differentiation. 
As endoglin had been observed in the cells surrounding the neural tube, its expression has been co-
localized with neural crest markers HNK-1 and SOX-10.22 However, not all identified neural crest cells 
expressed endoglin, thereby indicating a subpopulation of neural crest cells that were endoglin positive. 
As the embryo is examined in a rostrocaudal manner, it was determined that the neural crest cells 
expressing endoglin correlated with the cells that gave rise to vascular smooth muscle cells (SMC). The 
overexpression of endoglin in neural crest tissues leads to aberrant SMC development, however, it was 
determined that this was not due to defects in cell migration, but rather defects in the organization of 
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the vascular smooth muscle. These actions were also determined to be independent of TGF or BMP 
signaling, as there was no noticeable change in phosphorylation of pSmad 1/5/8 (BMP signaling) or 
pSmad2/3 (TGF signaling).  
 
Cardiogenesis 
 The above findings have been confirmed in human embryo studies, and endoglin has been 
demonstrated to play a later role in cardiac development. This was initially investigated because of 
previous studies demonstrating the presence of TGF during cardiac development,23 and the receptor 
profile for these factors had yet to be explored. Qu et al studied developing human embryos aged 4-8 
weeks for their expression of endoglin, and made the noteworthy observation that the expression of 
endoglin corresponded with TGF type I and type II receptors, along with betaglycan.24 These studies 
looked at the presence of endoglin in later organogenesis, and found its expression to correlate with the 
developing vasculature of kidney, lung, liver, neural tissues, and stomach. They further focused their 
studies on the developing human heart. Using qualitative antibody staining, it was found that endoglin 
was highly expressed on the primitive heart tube at 4 weeks development, and that endoglin co-stained 
with PECAM-1 on these tissues. Both endoglin and PECAM-1 were absent from myocardium. As the 
endocardial cushions make their first appearance from mesenchymal tissues at 5 weeks, a low-to-
medium amount of endoglin was detected. However upon the pronounced development of endocardial 
cushion tissues of the AV outflow tract, the mesenchymal cells produced a strong signal corresponding 
to a high expression of endoglin. The endoglin-expressing endocardium was also found to line the 
spongy myocardium at this 5 week mark. During the crucial 6-7 week period of development, endoglin 
again was found to be highly expressed in the mesenchymal cushions as they gave rise to the 
atrioventricular and semilunar valves. Endoglin was also found during this period to continue to be co-
expressed on the expanding endocardium with PECAM-1.  High levels of endoglin were also found 
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during the fusion of endocardial cushions to form the intermediate septum.  At 9 weeks, when the 
septation between the ascending aorta and pulmonary trunk has occurred and the semilunar valves are 
formed, endoglin expression finally decreased. By 12 weeks, a low, constant level of endoglin is found to 
be expressed on the residual mesenchymal cells on the semilunar and AV valves, and the intermediate 
aorticopulmonary septum.  
Table 1.1 CD105, associated molecules, in embryo/organogenesis 
Location Developmental Age (Human) Expression Level Colocalized Proteins 
Amniotic Fold
21












 Week 3 Moderate HNK-1, SOX10 
Primitive Heart Tube
24
 Week 4 Low/Moderate PECAM-1 
Endocardial Cushions
24




 Week 5 Low/Moderate PECAM-1 
AV Outflow Tract
24








 Week 6-7 Moderate PECAM-1 
Atrioventricular and Semilunar Valve Formation
24




 Week 9 Low 
  
Endoglin in Adult Tissues 
Endothelium and eNOS-signaling 
 The presence of CD105 has been found on numerous normal cell types in adult tissues, and its 
presence has been noteworthy in the development of several pathological states. As previously stated, 
endoglin is constitutively expressed in the adult endothelium. The role of endoglin for normal 
endothelial function has been well characterized.25 Toporsian et al show that endoglin is central to the 
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NOS-dependent dilation of arteries. Using vessels from haploinsufficient Eng+/- mice, HUVEC cells from 
patients with endoglin mutations, and proteinalysis, this group was able to determine that endoglin 
increases the stability of eNOS four-fold and that Ca2+ activation of eNOS is dependent on endoglin. It 
was also determined via immunoprecipitation assays that the endoglin-deficient HUVEC cells possessed 
Ca2+-activated eNOS with impaired interaction with HSP90. The interactions of these two proteins are 
necessary for maintaining NO levels.26 Because of this impaired interaction, cells deficient in endoglin 
had increased NOS-dependent O2
- production, suggesting that the role of endoglin is important for eNOS 
coupling. These findings correspond with their larger-scale findings of impaired myogenic responses in 
endoglin insufficient mice. They postulate that this crucial role of endoglin in regulating vascular tone is 
responsible for the venular dilation and capillary loss observed as early events in HHT1.  
 
Vascular Injury 
 As endoglin is involved in the development of vasculature and its normal regulation, several 
groups have investigated its presence and role during vascular injury. 27, 28 A definitive study published 
by Ma et al involved the observation of endoglin expression in porcine coronary arteries following 
balloon injury. In their work they document the expression of endoglin on endothelium, adventitial 
fibroblasts, and some medial smooth muscle cells prior to injury. In each of these cell types they 
determined a marked overexpression of endoglin that was sustained for two weeks after balloon injury 
to the arteries. Twenty-eight days following injury, the levels of endoglin were found to be low or nearly 
absent. Also, by staining human arterial sections removed from coronaries with complex plaques, they 
found there was an abundance of endoglin compared to a normal artery of the same subject. The 
interesting portion of their studies related to endoglin as a modulator of the effects of TGF1 on smooth 
muscle cells. In previous studies, smooth muscle cells (SMCs) were modulated and increased their 
migration potential when stimulated with Platelet Derived Growth Factor (PDGF), and this increased 
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migration was mitigated by the addition of TGF1 to cultures.29 Ma et al demonstrates here that 
decreasing endoglin lead to a decrease in TGF1’s ability to slow a PDGF-induced SMC migration.  
 Among other types of vascular injury, there has been much study and conjecture regarding 
endoglin’s presence in diseased arteriovenous malformations (AVMs). HHT1 patients suffer from AVMs 
globally,30 and therefore it is a point of interest to study the relation of endoglin to AVMs in patients 
who are not afflicted by phenotypic deficiencies in endoglin. Matusurba et al used samples from AVMs 
and normal cerebral vasculature in their 2000 study, localizing endoglin to several areas within the 
pathologic and normal cerebral vasculature.31 Namely, they found an expected expression of endoglin 
on the endothelium consistent with vasculature in other tissues, but also found endoglin in the 
adventitial layer in the leptomeningeal arteries, associating with the outer fibroblastic layer of the vessel 
wall. Surprisingly, it has been noted that endoglin positive adventitial cells were increased in cerebral 
AVMs, possibly as a result of shear stress on the vessels.  The presence of endoglin in areas of shear 
stress on vasculature has also been studied. In fact, in contrast to ALK1, endoglin mRNA is upregulated in 
in vitro conditions mimicking shear stress.32 These studies were performed in the context of examining 
endoglin insufficient (Eng+/-) mice after induction of limb ischemia.  
 
Ischemia 
 From all these data, it is clear that CD105 plays a role not only in maintaining normal vascular 
tone in the adult, but is also important for embryonic vascular development. However, angiogenesis in 
the adult – particularly with regard to reperfusion to ischemic areas, is where endoglin is most crucial. 
Hypoxia has been shown to be a potent signal for the expression of endoglin. Sanchez-Elsner et al 
describe the expression of endoglin regulated by hypoxia on a transcriptional level, as their studies 
conclusively show an increase in surface protein, transcript, and promoter activity of the endoglin 
gene.33 They also determined that a hypoxic response element exists downstream of the main 
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transcriptional start site of endoglin. HIF-1 modulates a suite of hypoxia response elements, including 
VEGF, erythropoietin, and iNOS.34-37 This group found that by binding a functional consensus HRE in the 
endoglin promoter, endoglin is also activated by HIF-1. They determined that when exposed to TGF, 
Smad3 works with Sp1 and HIF1 to cooperatively increase the expression of endoglin. Li et al have 
shown that the expression of CD105, however, blocks the ability of TGF to promote endothelial 
migration in HUVEC cells. This blockade contributes to angiogenesis.38 These two studies together would 
perhaps propose that endoglin expression as modulated by TGF is a form of negative feedback on the 
affected cell types.  
 
Hyperoxia 
 With hypoxia being an important mediator for the expression and function of endoglin, as 
described above, it is surprising that there have been very few studies related to the presence of CD105 
induced by converse, hyperoxic environments. Documentation of changes in eNOS in hyperoxia have 
been reported in the context of vascular formation for preterm-infants.39 Disruptions caused by the 
sudden increased oxygen tension in the underdeveloped infant tissues create problems in the eNOS and 
VEGF-related vascular development. eNOS and CD105 have also shown linked functionality through 
TGF-dependent Smad2 signaling.40 However, there have not been direct, correlative links between 
hyperoxia and the expression of CD105. The only documentation of changes in CD105 as a result of 
increased oxygen tension have been in the clinical contexts of neonatal bronchopulmonary dysplasia, 
where there was an upregulation in the expression of CD105 in pulmonary vasculature.41 This could be a 
direct, unanticipated result of the increased oxygen exposure in these tissues, or the by-product of fully 




Angiogenic Properties and Oncology Therapies  
 The propensity of endoglin expression to yield neovascularization has been of great interest to 
the field of oncology. CD105 as a target to halt angiogenesis in solid tumors is an attractive candidate for 
anticancer therapy. As CD105 is upregulated on activated endothelial cells, targeting CD105 during solid 
tumor development has been shown to thwart the necessary angiogenesis that would supply said 
tumor, limiting its growth.42 Burrows et al, having created a murine IgM monoclonal antibody that 
specifically binds to endoglin, claim that it binds exclusively to activated, developing tumor vasculature. 
They did not speculate as to the safety of using this in human therapy. However, more recently, anti-
CD105 antibodies bearing antitumor therapy have been demonstrated to home to and increase the 
permeability and retention of novel treatments.43  
CD105 and Adult Stem Cell Populations 
Hematopoietic Progenitors  
 Despite claims from groups which state that their anti-endoglin therapies target tumors 
specifically;44, 45 endoglin has shown to be a marker of cell types other than the vasculature. In fact, a 
long-term, repopulating hematopoietic stem cell population has been defined by the presence of 
endoglin.46. Chen et al isolated a side population of hematopoietic stem cells (HSC) marked by 
expression of SCL, which is needed for definitive hematopoiesis in the mouse,47 and characterized their 
marker profiles. The most notable finding was their confirmation that the endoglin-expressing early 
HSCs were more adept at producing long term repopulation of bone marrow cells in irradiated mice. 
Additionally, studies have been performed using embryonic stem (ES) cells to study endoglin’s role in 
the hemangioblast.48. Perlingeiro et al made use of Eng-/-, Eng +/-, and control ES cells and differentiated 
them toward the hemangioblast phenotype, and found that the presence of endoglin was necessary in 
CFC assays for the formation of blasts. Using flow, they determined that colocalization of endoglin and 
FLK-1 marked a very active hemangioblast population during differentiation.  
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 In addition to these important HSC and early hemangioblast lineages, endoglin is a marker for 
early erythroid progenitor cells. Several studies have demonstrated that endoglin increases 
concomitantly with CD235a in early erythrogenesis delineating from myeloid commitment, as CD45 
expression decreases. 49, 50 This is intuitive, as the previously discussed role for endoglin in hypoxia is 
well documented, and TGF signaling plays a role in erythropoietin synthesis. 51 Machherndl-Spandl et al 
characterize the immunophenotype of early erythroid progenitors from the mononuclear fraction of 
whole, uncultured bone marrow. Flow analyses provide distinct phenotypes of stages of early erythroid 
development, with the signal for CD105 being faint in stage A, but then becoming strongly pronounced 




 Another regenerative cell population has very recently been found to have endoglin as an 
important mediator for function. Heart-derived cardiosphere cells have been documented to show 
regenerative function in injured myocardial models, both by direct regenerative and paracrine effects.53 
Tseliou et al, of the same group, has recently elucidated a mechanism by which endoglin acts as a 
mediator for the TGF suppressing effects of cardiosphere cells in a chronic-ischemic model in rats. With 
the end goal to reduce fibrosis, they studied the paracrine effects of cardiospheres and found that 
soluble endoglin was present in the cardiosphere-conditioned media. They attributed the presence of 
endoglin in this soluble form to the presence of Metalloproteinase MMP14 on cardiospheres. Their 
findings are interesting as they demonstrate that soluble endoglin inhibits pSmad2/3 phosphorylation in 
a dose-dependent manner, and that the effects can be neutralized using an antibody directed against 
the extracellular domain of endoglin (which structurally corresponds to soluble endoglin). They also 
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demonstrate that the neutralization of soluble endoglin correlates to a decrease in collagen production 
by the dermal fibroblasts they utilized as target cells.54 
Mesenchymal Stem Cells 
MSC Identification 
 The MSC is an interesting population in which to finally examine the role of endoglin. As 
previously stated, there are inconsistencies in the marker profile as to whether or not CD105 should be 
considered as a marker for the MSC, as there exists a lack of consensus regarding MSC cell surface 
antigens. MSCs have been shown to differentiate in vitro into cardiac tissue, vascular tissue, adipose 
tissue, chondrocytes, and osteocytes. 55-59 They also exhibit the capacity for self-renewal and inherent 
mechanisms for immunomodulation. 60 61. Established methods of MSC isolation require a plastic 
selection phase of mononuclear cells, the source of which varies. Bone marrow, umbilical cord blood, 
Wharton’s jelly cells, and even adipose tissue manipulations have yielded cell populations which have 
been accepted as MSCs.58, 62-64  
 
MSC, Endoglin, and TGF Signaling 
 With such heterogeneity in the field, it is difficult to come to conclusions about the role of 
endoglin in the MSC, as the interaction between CD105 and other MSC “markers” (which may or may 
not be present) has not been identified. However, previous studies have been undertaken to investigate 
the role of TGF in this diverse population of cells. TGF1 signaling in bone resorption, as linked to 
osteoarthritis, caused migration and aggregation of MSCs, 65 and the inhibition of TBRI decreases this 
migration. Zhen et al observed the effects of TGF1 on Smad signaling in MSCs that were documented 
as only being positive for nestin. Their model was for the study of osteoarthritis, induced by a method of 
ischemic bone injury. The group did not investigate whether the hypoxia response elements were 
upregulated in this disease model of MSCs, as it would be anticipated that the CD105+ population of 
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cells increased in response to hypoxia. However, in their examination of Smad phosphorylation, this 
group determined that treatment with TGF1 of these isolated MSC groups resulted in a consistent 
dose-dependent increase in phosphorylation of Smad1/5/8. Interestingly, a marked contrast was 
evident in the MSCs from their ischemic model, with an increase in pSmad2/3 positive cells. They did not 
investigate whether this was facilitated by hypoxia response elements on the MSC, such as endoglin, but 
did note that it was mitigated by TBRI-inhibitors. 66 
 
ERK-MAPK and PDGF Signaling 
 Other signaling pathways, as we have previously described, are modulated by endoglin. While 
not specifically studying the role of endoglin, there has been a massive transcriptome study of the 
differentiation capacity of MSCs into different lineages and the molecular signaling involved in each. Ng 
et al differentiated mixed-sample MSCs (Lonza) into chondrogenic, osteogenic, and adipogenic lineages, 
and observed the whole-transcriptome changes in mRNA during each stage of differentiation. This group 
determined that ERK-MAPK signaling is globally important in the process of commitment and growth for 
all these lineages. PDGF signaling in these differentiated, mixed MSCs was associated strongly with the 
chondrogenic and adipogenic differentiation, and TGF signaling pathways were important in 
chondrogenesis specifically. They tested the importance of these two signaling pathways by blocking 
PDGF in addition to ALK5 of the TGF pathway. Their results were as predicted from their transcriptome 
studies. They also found that these two pathways are important for MSC growth, as their populations 
did not expand as easily as their uninhibited controls. 67 Other groups, however, have shown TBRII 
inhibition via microRNA-21 at the transcriptional and protein level to be important for adipogenesis.68 
However, as neither group characterized the expression of endoglin in these cells, the effect of CD105 




MSC Origin and Endoglin Expression 
 The heterogeneity in both source and marker profile has not gone unnoticed by all groups, 
however. Several papers have sought to characterize MSCs based on their source of origin and surface 
antigens. Gaafar et al undertook a large scale characterization of MSCs from endometrium and bone 
marrow to characterize their cytokine profile and expression levels of genes associated with 
multipotency and regeneration potential. In both populations, they detected a high concentration of 
CD105, but reported endometrial-derived cells had mildly greater (1.31-fold) expression of endoglin by 
mRNA analysis. While they did not speculate on the role of endoglin in the determination of the 
cytokine profile of each type, they did note that there was a greater propensity for these cells to express 
markers commonly associated with angiogenesis such as G-CSF, GM-CSF, KDR, WVF, WNTa and – to a 
lesser extent - GDF15,7, IL1b, ICAM1, ITGA6, NTE5, and BMP2 genes.69 
 
CD105 in MSCs for Regeneration 
 The source of origin of MSCs and the heterogeneity of marker profiles have also been explored 
in a functional capacity. Gaebel et al observed differences in CD105 expression in MSCs as it relates to 
healing performance capacity for cardiac regeneration, and used MSCs from different human sources. 
The primary analysis of this paper revealed that bone-marrow derived MSCs (BMMSC) and adipose-
tissue derived MSCs (ATMSCs) had a significantly higher proportion of cells which expressed CD105 as 
compared to cells derived from umbilical cord blood (CBMSCs). They also noticed that when taking a 
CD105-enriched population of CBMSCs for in vitro expansion, the amount of cells expressing CD105 
decreased. They did not determine if this resulted from down-regulation of endoglin expression within 
the MSCs, or if the CD105+ cells failed to expand as proficiently as their CD105- counterparts. The group 
further investigates the role of CD105 for preservation of cardiac function after ischemic injury. Using 
SCID mice, they examined the CD105-enriched CBMSCs and found their capacity for improving ejection 
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fraction was greater than their unaltered CBMSC correlates after LAD ligation. This improved function 
correlated well to the BMMSCs and ATMSC. They also demonstrated similar capacities of BMMSCs and 
their CD105-enriched CBMSCs to limit infarction size 6 weeks post-MI. Their subsequent analyses 
examine capillary density, fibrosis data, engraftment, apoptosis, and in vitro metabolic assays of the 
MSCs themselves. All of which were found to correlate the CD105-enriched CBMSCs with BMMSCs. They 
also performed an assay which observed capillary tube formation of only BMMSCs, one with 
endogenous expression of CD105, and the other which knocked out CD105 function using antisense 
phosphothiate-ODN. The untreated BMMSC group showed more favorable tube formation, indicating a 
predilection for neovascular formation. To date, this publication has been the most comprehensive in its 
characterization of CD105+ vs. CD105- MSCs. 2 
 The differentiation capacity of MSCs with respect to other lineages, however, has found that the 
lack of endoglin is a pro-osteogenic marker. Chung et al focused their studies on CD90 expression in the 
MSC, but nonetheless found that a low level of CD105 in the MSC population corresponded to an 
increased expression of osteoponin and osteocalcin at both 7 and 14 days into osteogenic 
differentiation.70 These data, along with studies that document greater propensities for CD105- MSC to 







Figure 1.3: Differentiation potential of MSC 
An illustration of the differentiation and expansion capacity of MSCs in vitro from various sources into several lineages, 
following exposure to specific growth/differentiation factors. The propensity for differentiation into several of these lineages 
has been studied with respect to CD105 expression. 
2, 70, 72, 73
 This figure was adapted and modified with permission from the 
work of Kode et al found in Cytotherapy 2009; Volume 11, Issue 4, Pages 377-391, under license agreement number 
4074420424818 from Elsevier and the Copyright Clearance Center.  
 
Role of Endoglin in MSC Immunomodulatory Capacity 
 However, in the immunomodulatory capacity of MSCs, the expression of endoglin has found to 
be limiting in capacity. In a paper which initially seeks to characterize MSCs derived from adipose tissue 
with respect to CD105 expression, there were some novel findings in both the expression on CD105 and 
characterization of some interesting multipotency markers. Anderson et al determined that CD105+/- 
ATMSCs had similar marker profiles with regard to CD29, CD44, CD49f, sca-1 and MHC class I positivity, 
and CD45 negativity. It was also noteworthy that they gathered data seeking to prove that CD105- cells 
were not of a more-differentiated phenotype. This was achieved by comparative studies where they 
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found no difference in cell size, proliferative CFU-F capacity, or expression of the following lineage 
markers: nanog (multipotency), PPAR-γ and LPL (adipogenesis), ALP and osteocalcin (osteogenesis) or 
Sox-9 (chondrogenesis).  There was an additional attempt to stimulate expression of CD105 with TGF1, 
but this did not yield an increased CD105 positivity. One interesting data point was that at confluency, 
their ATMSC’s surface expression of endoglin was decreased, but CD105 mRNA levels increased, 
however they failed to demonstrate that this was the action of MMP14 cleavage activity at the cell 
surface. However, subsequent analyses showed other important markers of the TGFsignaling family to 
be equivalent in both populations. This group showed that betaglycan, ALK1, ALK5, and TBRII were 
expressed at equivocal levels between CD105+/- ATMSCs by mRNA analysis.  
 The most novel portion of this paper, however, was the documentation of the differential 
capacity of CD105 on MSCs to modulate immune cells. Initially, there was a non-statistically significant 
increase in the production of TGF1 by CD105- cells. Subsequently, TNF and INF were used as 
proinflammatory cytokines on the CD105+/- cells. Stimulation with these compounds increased iNOS and 
IL-6 mRNA expression to a much greater extent in the CD105- group. Because both iNOS and IL-6 are 
important for T-cell expansion, an assay was devised using mitomycin-C treated MSCs of both groups 
with CFSE-labeled splenocytes. In a dose-dependent fashion of MSCs, CD105- cells proved more adept at 
suppressing CD4+ T-cell expansion in vitro. Because of this previously undescribed effect of a CD105- 
population as a more potent immunosuppressant, the group also sought to see if CD105- cells generated 
a propensity for activated macrophages to mature to a regulatory phenotype by the secretion of IL-10 




Figure 1.4: CD105 signaling for immunomodulation of specific immune-cell lineages 
Definitions: ASC
tot
 – total adipose derived MSCs, LPS – lipopolysaccharide, PGE2 – prostaglandin E2, M– macrophage. (A) The 
levels of PGE2 and TGF-β1 concentration from supernatants by ELISA, measuring relative concentrations for CD105+/- ASCs 






 mASCs were stimulated with TNF-α (10 ng/ml) and IFN-γ (10 







 ASCs were cultured with splenocytes (200,000 cells/well) and stimulated with anti-CD3 (1 
µg/ml) for 72 hours, and proliferation of CD4
+
 splenocytes was quantified. (D) BM-MΦs cultured in presence or absence of ASC 
for 48 hours followed by restimulation with LPS (1 µg/ml) for 24 hours. Concentration of IL-10 and IL-12 from the co-culture 
supernatants were measured using ELISAs. Data are shown as mean (SEM).  This figure was adapted from the work of Anderson 
et al from their publication in PLoS One,
3
  and did not require permission as it is derived from an open-access article (PLoS One, 
2013; Volume 8, Issue 10, Pages e76979) distributed under the Creative Commons Attribution Non Commercial License. 
 
Summary 
 There are several pieces of evidence that have yet to be determined which will complete the 
picture of CD105 in the MSC. The first is a consensus marker profile by which to define the mesenchymal 
stem cell. As previously stated, there are contradictory reports regarding the use of CD105 as a marker 
for a sub-set of MSCs with distinct capabilities, because there is such heterogeneity in the population. 
The second is that the mechanism by which endoglin functions to provide these differing MSC 
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capacities, which has been demonstrated of endoglin in other cell types. As the field stands, the 
characterization of CD105+ versus CD105- cells is primarily characteristic instead of mechanistic. 
Discussed here were several papers commenting on differentiation and functional capacities of these 
two different cell types, but there was very little decisive, conclusive evidence of how endoglin plays a 
role in its capacities. Additionally, there has been work on cytoskeletal organization of the MSC,74-76 
none of which even consider the differential expression of endoglin as a target for investigation, as it 
was in endothelial cells. A greater understanding of endoglin’s role in TGF, BMP signaling, and TGF 
independent mediated effects should be undertaken in order to explain the variety of phenotypic 
differences in these two distinct MSC populations.  
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Chapter 2: Exploration of the Immunomodulatory Capacity of Mesenchymal 
Stem Cells on CD4+ and CD8+ T-cells with respect to Endoglin Expression in 







 The immunomodulatory capacities of MSCs and their suppressive mechanisms have been 
extensively explored. However, a lack of consensus in the definitive, identifying marker profile for MSCs 
may have consequences in terms of a given MSC-population’s immunomodulatory efficacy. Endoglin 
(CD105) expression is one such debated marker, and its presence indicates a cell type with a modified 
functional capacity compared with the CD105- counterparts. Additionally, MSCs are presently used in 
trials for cell-therapy, some in allogeneic settings. This study seeks to replicate immunosuppressive 
syngeneic in vitro effects of MSCs on CD4+ and CD8+ T-cells, and apply the created methods in an 
allogeneic context.  It also explores the differentiation of CD4+ T-cells in co-culture with CD105+/- MSC 
populations in the syngeneic and allogeneic settings.  
 Bone marrow MSCs were harvested from C57BL/6J mice, and sorted for a CD45-/c-kit- 
/CD90+/Sca-1+ expression profile. This population was sorted for CD105 for the establishment of 
experimental groups. Splenocyte and experimental CD4+ and CD8+ subgroup proliferation was tracked 
using CFSE. CFSE-signal tracking was employed in titrating doses of stimulation antibodies for 
proliferation cultures, and determining effective methods for MSC-splenocyte co-culture. From the 
results of these experiments, a ratio of 1 MSC for every 5 splenocytes was employed in a transwell 
culture system. Experimental splenocyte populations were stimulated with a combination of plate-
bound anti-CD3 and anti-CD28. The CD105+/- MSCs were subsequently irradiated and placed in a 
transwell co-culture system with stimulated CD4+ or CD8+ splenocytes in syngeneic and allogeneic co-
culture systems, respectively. In the differentiation culture, the CD4+ cells and supernatants were 
harvested after differentiation and restimulation. mRNA levels of Th1/Th2/Th17/Treg-associated factors 
were assessed from the differentiated CD4+ populations. Th1/Th2-cytokine production was quantified in 
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these supernatants to determine functional differences between differentiation in the experimental 
groups. 
 Previously documented proliferation analyses that employed antibody-only stimulation used the 
anti-CD3 concentration of 10g anti-CD3/mL (plate bound) and 5g/mL of anti-CD28 in the soluble 
phase. This method consistently produced no stimulatory effect for all splenocyte populations. Titration 
and manipulation of the antibody method led to the necessary combination of 10g anti-CD3/mL and 
5g/mL of anti-CD28 being plate bound. Comparison of direct co-culture and transwell co-culture 
methods produced an MSC-washout artifact in the direct co-culture group. This necessitated that all 
MSC/splenocyte co-cultures be performed in a transwell system. This system was further optimized by 
examining the necessary doses of MSCs to induce suppression, and the appropriate timeframe in which 
to examine the results. It was found that a ratio of 1 MSC for every 5 splenocytes was optimal at 
producing expression without exhausting the cultures, and the most consistent suppression was seen at 
48 hours after induction of co-culture.  
 Using these optimized co-culture conditions, the effect of CD105 expression on MSCs for the 
suppression of CD4+ and CD8+ syngeneic and allogeneic co-cultures was examined. Though no results 
reached significance, CD105- MSCs produced the highest degree of suppression compared to their 
CD105+ counterparts in both syngeneic and allogeneic CD4+ co-cultures. However, while the trend was 
maintained for CD8+ syngeneic cultures, there was a slight stimulatory effect produced in the CD8+ 
allogeneic model.  
 For the CD4+ differentiation assays, changes in transcription favoring a Th2-phenotype were 
most pronounced in the allogeneic contexts. In the case of IL-10, IL-4, and GATA3, CD105- allogeneic co-
culture groups also demonstrated increased expression compared to the CD105+ allogeneic populations. 
Th1/Th17 associated transcription factors were largely downregulated in all allogeneic experimental 
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populations. The syngeneic groups, showed consistent downregulation corresponding with the lack of 
CD105 expression. Confirmation of these phenotypes by quantification of Th1/Th2-secreted factors 
revealed consistent patterns with IL-4 and IL-10 production and their corresponding expression data. 
The Th1-associated cytokines, IL-2 and IFN, did not follow the pattern associated with expression. IFN 
production was markedly increased compared to controls in the CD105+ and CD105- experimental 
populations, though the CD105- group produced less IFN than the CD105 in both allogeneic and 
syngeneic contexts. The pattern of IL-2 production differed from IFN in that the CD105- allogeneic cells 
produced less IL-2 production than controls. This was the only setting that demonstrated this decrease. 
CD105+/- patterns in the syngeneic context of IL-2 production opposed those documented in the IFN 
assay.  
 Changes in transcription and secreted factors indicate that MSCs in an allogeneic differentiation 
culture promote CD4+ cells toward a Th2 phenotype, with dependence upon the lack of CD105 
expression for maximal induction. However, these studies indicate that the dynamic culture system did 
not eradicate all traces of Th1/Th17 lineages as seen by both the expression and secretion of these 










 There still exist many mysteries in the basic physiology of Mesenchymal stem cells (MSCs). It is 
known that MSCs from different sources behave differently in proliferative, differentiation, and colony 
forming capacities. Kern et al observed in their 2006 study that MSCs derived from bone marrow, 
adipocyte tissue, and umbilical cord blood are distinctly and quantitatively different in each of the 
aforementioned capacities.77 Presently, the only consistency in the identification of a MSC population is 
its ability for plastic adherence, capacity for self-renewal, the ability to differentiate into cardiac, 
adipocyte, and vascular lineages, and the maintenance of immune-privilege. In fact, one review article 
by Kolf et al illuminated the fact that, despite hundreds of publications on MSCs, there are vast 
inconsistencies within the surface-marker profile employed to definitively identify a MSC.1 
 Endoglin (CD105) is a marker most known for its presence on endothelial cells.78 While this 
protein is known as a member of the TGF- receptor family, it has been studied thoroughly in the 
context of angiogenesis in solid tumor models. Endoglin expression is also induced on MSCs by culture in 
hypoxic conditions.79 Interestingly, there has been some study of endoglin and MSC-related 
differentiation studies, showing down-regulation when MSC are differentiated into connective tissue 
cell types.80 There have also been studies which indicate that the absence of CD105 on MSCs, 
presumably due to its capacity to modulate TGF signaling, results in a significant effect upon the 
proliferative capacities of several immune-cell populations.3 
 MSCs have the ability to modulate the immune system, and this modulation has been 
documented to create "immune privilege." This immune privilege is accomplished through several 
methods, including the production of anti-inflammatory cytokines such as Interleukin-10 (IL-10), 
Interleukin-5 (IL-5), Interleukin-6 (IL-6), and Transforming Growth Factor TGF.81 These cytokines 
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alone have been shown to inhibit the proliferation of activated-T-cells, including MSC-induced inhibition 
in an allogeneic context.82 . In addition to these suppressive cytokines, MSCs also have decreased MHC 
expression, allowing them to persist in allogeneic settings.61 This makes these cells attractive candidates 
for cell therapies, and indeed, MSCs have been used for their capacity of immunomodulation to induce 
tolerance in clinical trials of graft vs. host disease.83 However, despite this, few groups have sought to 
explore the corresponding link between the immunomodulatory capacities of CD105- MSCs in culture 
with T-cells, which would play the major role in their rejection. 
 By studying the characteristics of CD105- and CD105+ MSC populations, in comparison with an 
unfractionated set of MSCs, we will identify which MSC phenotype is most apt to suppress specific 
immune-populations.  If indeed there proves to be a difference in the immune modulating properties 
between the CD105-expressing phenotypes, it would be concerning for the in vivo maintenance of MSCs 
for cell therapies, including any subsequent downstream differentiated cells derived from an allogeneic 
source. In the following chapter, CD4+ and CD8+ T-cell suppression by MSCs with differential CD105 
expression will be explored in the context of syngeneic and allogeneic in vitro models. This study 
includes optimizations of this in vitro model based on previous literature and our own laboratory 
findings.  This chapter will demonstrate the characterization of CD4+ T-cell differentiation as a product of 







 MSCs were procured from young-adult C57BL/6J mice (Jackson Laboratories). Previous data 
have shown that the MSC population available for isolation from bone marrow decreases as the mice 
age.84 While this study was done in the context of MSC conversion to osteogenic progenitor cells, it has 
been noted in methodology that younger mice yield higher numbers of mononuclear cells from bone 
marrow extraction than their older counterparts, as younger marrow is more cellular than the adipose-
laden aged marrow.85 Therefore, all MSC extraction was performed on mice 9-11 weeks of age. The 
C57BL/6J mice were sacrificed by means of carbon dioxide asphyxiation, followed by opening of the 
chest cavity, in accordance with the approved animal usage protocol established. From here, the murine 
corpse was submerged in a 70% solution of 2-propanol (Fisher Chemicals) to limit contamination from 
the exterior of the mouse during bone isolation, and placed in a biosafety cabinet for manipulation in 
the following steps.   
 By removing skin and soft tissue over the femur, tibia, hip, and disarticulating the joints 
surrounding those bones, the bones were isolated and placed in an extraction medium. This medium is a 
filtered mixture of Dulbecco’s Modified Eagle Medium (DMEM)-F12 (Invitrogen), 2% fetal bovine serum 
(FBS) (GIBCO), and 1% penicillin/streptomycin (5,000 g/mL) (Cellgro). The bones were subsequently 
snipped at opposite ends, and flushed with this same medium into a new, separate culture dish. After a 
filtration step through a 70 m cell strainer to remove any bone fragments or soft tissue that may have 
escaped the bones during flushing, the cells were washed, counted for efficiency of extraction, and then 
separated by means of a high density, low viscosity separation medium, known as Ficoll-Paque (GE 
HealthCare). After layering the cell-suspension over the Ficoll, the Ficoll-cell suspension was centrifuged 
at 300g, 4oC, for 30 minutes with the brake off. Following this centrifugation step, distinct layers of cells 
are visible, and a mononuclear layer was identified by its position between the medium and Ficoll. This 
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mononuclear layer was carefully removed and washed twice with extraction medium to remove all 
traces of the separation procedure, and cells were counted for efficiency and plated on tissue-culture 
treated, plastic culture dishes.  
 As previously stated, mononuclear cells with plastic adherence are the minimum criteria for 
being classified as an MSC. Additionally, once plated, they are cultured in the same DMEM-F12 based 
medium, with a higher (10%) concentration of FBS. This medium is created as a low-glucose medium, 
which will not meet the energetic requirements of the non-adherent, non-mesenchymal mononuclear 
cells derived from bone marrow. These cells were cultured at 37oC at normoxic conditions, with 5% CO2. 
3-4 days following extraction, after the MSCs have had time to adhere, the non-adherent mononuclear 
cells, unable to grow in the low glucose environment of the DMEM-F12, were siphoned off. The cells 
were passaged when they had achieved 80% confluence. 
Flow Cytometry Based Sorting for CD105+/CD105- populations 
 Removal of the adherent MSCs was accomplished with a thin layer of 0.25% Trypsin EDTA 
(Cellgro) and placed at 37oC for approximately 5 minutes, or until the MSCs began to release from the 
plastic. From there, those cells were washed and stained with a combination of antibodies for an initial 
sorting. The first sort is for CD90+,Sca-1+, CD45- c-kit- cells using titrated concentrations of the following 
fluorescently conjugated antibodies: CD90.2-APC, Sca-1-PacBlue, CD45-FITC, and CD117 (c-kit)-PE 
(BioLegend). The final separation was for the establishment of experimental groups as described below. 
A titrated concentration of anti-mouse CD105-APC antibody was applied to the CD45-/c-kit- /CD90+/Sca-
1+ selected MSCs, thus establishing a set of CD105+ and CD105- MSCs.  
Splenocyte Isolation and Sorting 
 Splenocytes were harvested from 9-30 week-old male C56BL6/J or C3H/HeJ mice (Jackson 
Laboratories). The age range was increased for the splenocyte harvest to reflect the flexibility during 
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which these mice maintain a normal, healthy adult immune-phenotype.86 The mouse strain C3H/HeJ 
was selected due to the extreme differences in histocompatibility, based on the protein configuration of 
the alloantigen markers between itself and the C56BL/6J mice. A table of alloantigen protein types in 
different mouse strains was procured from BioLegend.  
 Mice were sacrificed here in an identical fashion to the method described above. To harvest the 
spleen, an incision was made on the left dorsolateral side of the mouse, just inferior to the rib cage. The 
spleen is clearly visible through the peritoneal sac when opened from this angle. A second small incision 
was made directly lateral of the spleen tip, and the spleen was removed through this incision. Ensuring 
there was no extraneous tissue from the peritoneum, the spleen was transferred to a small culture dish 
containing enough supplemented RPMI to completely cover the organ. Supplemented RMPI consisted of 
a base of RPMI-1640 without L-Glutamine (Fisher Scientific), with 10% FBS (GIBCO), 5% 
Penicillin/Streptomycin (5,000 g/mL) (Cellgro), 5% MEM-Non-essential Amino Acids (100x) (Corning), 
5% Sodium Pyruvate (100mM) (Corning), 5% L-Glutamine (200mM) (Corning), and 0.025 mol 2-
mercaptoethanol (Sigma-Aldrich).  
 Using a 100m cell strainer and the plunger of a syringe, the spleen was ground into a single cell 
suspension, before being strained through a second 100m cell-strainer into a centrifuge tube.  Cells 
were pelleted at 300g for 5 minutes at 4oC, and the supernatant was subsequently aspirated. Cells were 
then suspended with 5mL of RBC Lysis Buffer (eBioscience) per spleen, and incubated at room 
temperature for 10 minutes with occasional gentle agitation. Cells were again pelleted using the same 
centrifugation parameters as listed above. After aspiration of the RBC-lysis buffer, the cells were then 
counted for proceeding directly with antibody incubation for sorting, or for proliferation-staining.  
 Cells were sorted using titrated concentrations of murine anti-CD4-PE (BioLegend) and anti-CD8-
APC (BioLegend) for the experiments that required these T-cell populations. Experiments that required a 
CD3+ enriched splenocyte group, a CD3-Magnisort Kit (eBioscience) was employed according to 
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manufacturer’s instructions. When the experiments required whole-splenocytes, the cells were re-
suspended in cold 1x Phosphate Buffered Saline without calcium or magnesium (PBS) (Corning) to 
commence proliferation staining.  
Proliferation Staining 
 Cells that required carboxyfluorescein succinimidyl ester (CFSE) (eBioscience) staining for 
proliferation analyses were rinsed twice in cold 1xPBS. After the second wash, cells were re-suspended 
at a concentration of 2x107cells/mL, again in cold 1xPBS. An equal volume of 20M CFSE was created 
from 5mM CFSE stock in cold PBS. These CFSE-containing and cell-containing volumes were combined 
and incubated for 10 minutes at room temperature. The reaction was quenched by adding 10mL of cold, 
supplemented RPMI. The cells were washed twice in cold, supplemented RPMI, and the CFSE-signal was 
quantified by flow for a baseline in these proliferation analyses.  
Proliferation Assays and MSC Co-culture  
 To induce proliferation, mouse anti-CD3 (eBioscience) and anti-CD28 (eBioscience) were 
employed in varying concentrations according to the experimental parameters (listed below). As a result 
of these experiments, the most effective method to induce T-cell stimulation was binding of 10g/mL of 
anti-CD3 and 5g/mL of anti-CD28 to non-tissue culture treated plates. This was accomplished by 
creating a plating mixture of these antibodies at the aforementioned concentrations, and coating the 
bottom of the plates. The plates were then incubated at 37oC for 1-2 hours, and allowed to cool to room 
temperature. The wells were then washed twice with room-temperature 1xPBS, and supplemented 
RMPI was added to the wells to receive the splenocyte populations under examination. 
 For the direct-contact co-cultures described in the experiments below, 5x104 MSCs of different 
experimental populations were added to the antibody-treated plates at this step. For the transwell co-
culture systems described in the experiments below, varying experimental doses of MSCs were added to 
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the 0.4m polycarbonate-membrane transwell inserts (VWR).  When the optimal dose of MSCs was 
determined at a ratio of 1 MSC for every 5 splenocytes from the results of these experiments, all MSCs 
were plated at a concentration of 5x104 MSCs per transwell insert. MSCs were irradiated prior to their 
placement in co-culture at a dose of 30Gy by x-ray irradiation, as determined by previous studies87 to be 
a functional mitotically-arresting but non-lethal dose. 
 For each of the co-culture assays, 2.5x105 CFSE-labeled splenocytes of different experimental 
populations were added to each of the antibody-coated wells and cultured with or without the MSC 
populations in supplemented RPMI. CFSE signals and analyses were conducted using BD FACS Diva 
software or with FlowJo. The CFSE results were tabulated and analyzed, employing a Student’s t-test 
assuming equal variances for the calculations of statistical significance.  
Differentiation Assays 
 In the differentiation assays, 2.5x105 CD4+ splenocytes of different experimental populations 
were added in a 5:1 ratio to each of the antibody-coated wells and cultured with or without the MSC 
populations in supplemented RPMI. 72 Hours after initiation of co-culture, the MSC-containing transwell 
inserts were removed. The CD4+ populations were harvested and washed in a 1x PBS solution, then re-
plated onto fresh, stimulation antibody-coated plates in supplemented RPMI. These cultures were 
allowed to expand for 24 hours, where the cells and supernatants were collected for analyses.  
RT-PCR of Differentiated Splenocytes 
 Cells from the differentiation cultures were harvested as described above, washed in PBS, and 
resuspended in 1mL TRIazol reagent (Fisher Scientific). After a 5 minute incubation at room 
temperature, 200L chloroform (Sigma Aldrich) was added to the samples, and briefly agitated. The 
samples were then centrifuged for 15 minutes with a speed of 12,000 RCF at 4oC. The aqueous layer was 
isolated after this centrifugation, and placed in a new tube. 500mL of 100% isopropanol (Fisher 
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Scientific) was added to the aqueous layer. The samples were then incubated at -20oC for 20 minutes. 
Following the incubation, the samples were centrifuged for 10 minutes with a speed of 12,000g at 4oC. 
The supernatant was removed, and the pellet was washed with 1mL of 75% ethanol (Fisher Scientific), 
and returned for a final centrifugation step for 5 minutes at 7500g. The supernatant was removed and 
the pellet allowed to dry for 15-20 minutes prior to resuspension in water. Concentrations of RNA were 
measured using a BioTEK Take 3 instrument and Gen5.1.11 software.  
 To create the cDNA library, 1g of RNA was taken from the extraction described above and used 
in a reverse-transcription kit (BioRad), adjusting the volume with water to 16L dependent on the 
concentration of RNA in the sample. 4L of the reverse-transcription mastermix was added to the RNA-
suspension, and the reaction was placed in an Eppendorf Mastercycler Gradient Thermocycler. The 
reaction was incubated in the thermocycler for a priming step lasting 5 minutes at 25oC. This was 
followed by the reverse-transcription step for 30 minutes at 42oC, and finally 5 minutes at 85oC to 
inactivate the reaction.  
 The resultant cDNA from the reverse-transcription step was quantified prior to initiation of 
qPCR. 50pg of the cDNA product was required for each quantifying reaction. Keeping the reaction on ice, 
the cDNA was diluted to a concentration of 16.67pg/L, and 3L were transferred into 5L of EvaGreen 
qPCR Mastermix-low ROX (MidSci). 2uL of 10uM factor-specific primer pairs were added to the reaction. 
Primer sequences can be found in supplemental table S2.1. Each qPCR reaction was performed in 
triplicate, and was cycled and analyzed in a sealed 384-well plate, using an Applied Biosystems ViiA7 
instrument. Cycling conditions during the quantification consisted of an initial hold for 10 minutes at 
95oC. This was followed by 40 cycles of 95oC for 5 seconds with a subsequent 30 seconds at 60oC. The 
temperature cycled at 1.6oC per second.  
 The resultant CT values from each of the reactions were normalized using the CT values of 
hypoxanthine phosphoribosyltransferase (HPRT) as an internal control, creating a CT value for each 
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sample. The CT was calculated by subtracting the factor-specific CT from a non-co-cultured (NCC) 
controls. The fold change was calculated by the following equation: 
𝐹𝑜𝑙𝑑 𝐶ℎ𝑎𝑛𝑔𝑒 =  2−(∆∆𝐶𝑇) 
The fold changes for each group were tabulated and analyzed. Statistical comparisons were made using 
the Student’s t-test assuming equal variances.  
Quantification of Secreted Factors 
 Confirmation analyses for the Th1/Th2 differentiation were conducted on the supernatants 
harvested 24 hours after the restimulation of the MSC-co-culture groups (as described above). ELISA 
assays were performed for Interferon IFN, Interleukin-4 (IL-4), Interleukin-2 (IL-2), and IL-10 using a 
Mouse Th1/Th2 ELISA Ready-SET-Go Kit (eBioscience) according to manufacturer’s instructions. The 
necessary dilution of the supernatants was titrated in order to produce quantifiable signal for each of 
these factors. The completed reactions were subjected to absorbance spectroscopy using a BioTek plate 
reader using Gen5.1.11 software 450nm and 570nm.  
 For the analysis of these ELISA plates, the absorbance values from 570nm were subtracted from 
the absorbance at 450nm. Using the concentrations of standard curve for each factor as provided by the 
kit, linear regression models for correlating the concentration to absorbance were created. The equation 
generated by the factor-appropriate regression model was subsequently employed to quantify the 







 In order to document a change in proliferation, a splenocyte stimulation assay was necessary to 
construct. Previously documented studies have shown that using a plate-bound anti-CD3 and soluble 
anti-CD28 have successfully induced T-cell specific stimulation and subsequent proliferation.88 This was 
preferred over using phytohemagglutinin for activation, as it more closely mimics the 
mechanism induced for T-cell proliferation by antigen-presenting cells. One such protocol was 
attempted. Splenocytes from C56BL/6J mice were isolated and stained using CFSE as a measure of 
proliferation. These splenocytes were placed in culture in the appropriate supplemented RMPI medium 
(see methods) with plate-bound murine anti-CD3. For these assays, the anti-CD3 concentration was 
10g anti-CD3/mL PBS. 5g/mL of anti-CD28 was added to these cultures in the soluble phase. CFSE 
signal was tracked in these cells over a period of 4 days. The percentage of cells that had divided in 
these cultures was determined by the construction of a gate on the histogram plot of CFSE signal, within 
the subpopulation of splenocytes falling within the expected size-range. Using the unstimulated control 
as a guide, the demarcating CFSE signal was determined for each experimental replicate to distinguish 
dividing cells from the other quiescent splenocytes. As documented in Figure 2.1A by representative 
images, these cultures produced no stimulation compared to their unstimulated controls.  
 Thus, the combination of stimulating antibodies that would result in proliferation of T-cells was 
reassessed. By incubating the anti-CD28 to bind to the non-tissue culture-treated plate concurrently 
with the anti-CD3, a proliferative effect was produced. This was titrated at varying doses of anti-CD3 at 
100 g/mL, 10 g/mL, and 1g/mL in PBS during antibody plating. In Figures 2.1B and 2.1C, the CFSE 
signal of the splenocyte cultures is displayed for 24 and 48 hours after the initiation of culture, 
respectively. Even at the lowest concentration of anti-CD3, the addition of the plate-bound anti-CD28 to 
the proliferation assay created a stimulatory effect on the T-cells in culture. Within the first 24 hours, 
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cells began to divide in a dose-dependent manner (Figure 2.1B). By 48 hours after induction of 
stimulation culture, 59.3% of splenocytes had demonstrated at least one division even at the lowest 
concentration of anti-CD3. The stimulation also had increased in a dose-dependent manner at 48 hours, 
but with very little differences between the 10g/mL and 100g/mL anti-CD3 doses. Therefore, in each 
of the subsequent assays, a plated antibody concentration of 10g/mL anti-CD3 and 5g/mL anti-CD28 




Figure 2.1: Dosage comparison of stimulation antibodies for splenocyte proliferation. 
(A) Histogram of cell count by CFSE signal, 4 days after initiation of stimulation culture with only plate bound anti-CD3. Anti-
CD28 was in soluble phase for these assays. The area designated by P3 in both panels indicates a weaker CFSE signal, typically 
indicating that the cells in these populations have divided. P3 on the left, control panel (without stimulation) contained 34.1% 
of the parent population gated from FSC and SSC for size. P3 on the right had 34.2% of the parent population; therefore 
containing no differences, despite treatment with 10g/mL of plate bound anti-CD3 and 5g soluble anti-CD28. (B) Histogram 
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of CFSE stained splenocytes, 24 hours after incubation with plate bound anti-CD3 and anti-CD28 at varying concentrations of 
CD3. Panels left to right indicate 0 stimulating antibodies, 1g/mL of anti-CD3 with 5g/mL anti-CD28, 10g/mL of anti-CD3 
with 5g/mL anti-CD28, and 100g/mL of anti-CD3 with 5g/mL anti-CD28, respectively. These panels display a population 
selected for size by FSC and SSC. In each panel, P6 was created using the non-stimulated population to gate for divided cells. 
The cells without stimulation showed 12% of the parent population of having a halved CFSE signal, indicating division. The 
percentages for the increasing populations were 14.1%, 22.1%, and 26.5% for 1, 10, and 100 g/mL anti-CD3, respectively. This 
demonstrates a population beginning to divide as a result of the combination of plate bound antibodies. (C) CFSE stained 
splenocyte stimulation cultures, structured in the same manner as described in part B, 48 hours after initiation of culture. 
Population P1 was created using the non-stimulated culture as a control for divided cells, indicating 4.9 % having divided 
without stimulation. There was a clear set of divided cells as indicated by the CFSE peaks. The percent divided of each 
increasing plate-bound anti-CD3 concentration was: 59.3%, 66.5%, and 66.7% for 1, 10, and 100 g/mL anti-CD3, respectively. 
Optimization of MSC Co-Culture Conditions 
 In their review article, Yagi et al assert that MSCs can affect their surrounding cells by both 
paracrine signaling and via direct contact.89 To determine the most effective method by which to assess 
T-cell proliferation in the presence of MSCs for the subsequent experiments, a comparative study was 
conducted between direct co-culture and transwell co-culture. This study was initially comprised with 
multiple experimental variables, including the investigation of how the expression of CD105 on the 
CD90+, Sca-1+, CD45- c-kit- MSCs affects proliferation. It also utilized splenocytes from both C56BL/6J and 
C3H/HeJ mice, in an attempt to explore differences in an allogeneic and syngeneic setting. CD105+ and 
CD105- MSCs were irradiated at 30Gy, and then plated in either direct or transwell stimulation cultures 
with CFSE-stained splenocytes from C56BL/6J or C3H/HeJ mice, in a ratio of 1 MSC for every 5 
splenocytes. Proliferation was analyzed every 24 hours for 3 days. 
 However, upon reviewing the data, a MSC-washout artifact was discovered in the cultures that 
had direct contact. Figure 2.2A displays images of example cultures, taken after the artifact was found in 
the non-stimulated controls for the study. While there are more residual splenocytes in the harvested, 
direct contact samples, there are also no visible MSCs. MSCs, being plastic adherent cells, should still be 
present in the culture dishes after the process of splenocyte collection. In Figure 2.2B, the artifact of 
non-CFSE stained MSCs is clearly visible in the percentages indicated by the divided-cell gate compared 
to both the transwell cultures, and the cultures allowed to proliferate in the absence MSCs. These 
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images and analyses were both from CD105+ cultures in an allogeneic context, and therefore these 
differences cannot be due to experimental variables. The MSC-washout artifact was found in both the 
visualization and the CFSE-analyses of direct-contact cultures, regardless of CD105 expression or 
splenocyte source (data not shown). It is suspected that the necessary stimulating-antibody coating on 
the plates prevented proper adherence for these cells. Therefore, for the subsequent analyses, all 
suppression assays by MSCs were performed in a transwell setting, such that the MSC-washout artifact 




Figure 2.2: Optimization of co-culture assays for MSCs and splenocytes 
(A) Representative images of co-culture dishes after cell collection for analysis. These images were procured from 48-hour 
stimulated co-cultures between CD105
+ 
MSCs and CFSE-labeled splenocytes. As visible in the central panel, there were still 
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several blasting splenocytes remaining in the culture after rinsing the plates, but there are no visible MSCs, indicating that the 
adherent MSC population was isolated with the splenocytes. There were no expected MSCs in the left and right panels, where 
MSCs were either not present or were present in a removable transwell insert. (B) The MSC-washout effect is visible in the 
CFSE-based proliferation analyses for the splenocytes. P3 on all three panels was created based on the CFSE fluorescence 
pattern from the assays which contained neither stimulating antibodies nor MSCs. This gate applied to the subsequent analyses 
demonstrated a distinct population in the non-stimulated, direct contact co-culture without CFSE signal, indicating the MSCs 
were present in the gates needed to analyze the proliferation of the splenocytes, artificially skewing the analyses. 
 
Optimization of Suppression Timeline and MSC Dosage 
 The analysis of T-cell proliferation has been extensively documented. There are multiple 
methods that have been devised to track and report the frequency at which various T-cell populations 
are dividing.90, 91 However, with each different experimental manipulation of a T-cell expansion system, 
there are correspondingly different timeframes in which the T-cells are observed in order to conclude 
the efficacy of experimental effects upon proliferation.92 To determine the timeframe in which the MSCs 
show the greatest effect upon CD3+ T-cell expansion, CFSE-tracked proliferation was observed every 24 
hours over the course of 3 days.  
 Additionally, there have been previous studies that demonstrated a dose-response in the 
suppressive effects of MSCs on T-cells, corresponding to the ratio of MSCs:T-cells in the suppression 
cultures. Increasing the dosage of MSCs creates a greater suppression of proliferation.3  Therefore, in 
order to optimize the MSC:T-cell ratio at which these suppression assays should be performed, 
increasing doses of irradiated, CD90+, Sca-1+, CD45- c-kit- MSCs were added in a transwell system to 
CD3+-splenocyte stimulation cultures. The MSCs were unsorted for CD105. The MSC:T-cell ratios in these 
studies were as follows: 2:1, 1:1, 1:5, and 1:50. The T-cells were placed in the bottom chamber, such 
that they could maintain contact with the plate-bound stimulating antibodies. The MSCs were placed in 
the upper chamber. A schematic of this experiment can be found in supplemental Figure 2.S1.   
 Figure 2.3A shows an example of the analyses used to assess the percent of the CD3+ population 
that had divided in these cultures. The CFSE-stained, CD3+ cells were gated for the expected sizes of the 
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proliferating and quiescent lymphocyte populations. A gate was constructed using the non-stimulated, 
CFSE control and the unstained samples. This was done to ensure that an accurate measure of the cells 
containing a CFSE-signal (at a lower level than the non-dividing population, but still containing CFSE) 
were the substance of the percent-divided population. These gates were then applied to the 
experimental samples of that particular time point, as the fluorescent signal of CFSE decreases with 
time. An example of these gates as applied to the 48-hour time-point on four of the experimental 
MSC:T-cell ratios may be found in Figure 2.3B.  
 At 24 hours, the CD3+ splenocytes had not yet completed a division, as seen in Figure 2.3C.  
However, after 48 hours, cells had undergone several divisions. The unsorted MSCs in culture produced 
a distinct suppression in all groups. However, the dose-response that was previously reported was 
unable to be replicated in these assays. In fact, the 2:1 and the 1:5 ratios of MSCs:T-cells produced 
similar suppression at having 58.26%±6.74 and 61.08%±6.23 divided cells, respectively. This compares to 
the stimulation cultures without MSCs, which had a percent divided at 74.54%±3.07. After 72 hours in 
culture, the CD3+ cells had proliferated to the extent that the percent divided was not reduced 
significantly at any MSC dosage, and there was again no correlation of a dose-response. Data for each 
time-point and cell-dosage can be found in Figure 2.3C. Therefore, for the subsequent assays where the 
experimental variable of CD105 expression could affect T-cell populations in their proliferation, all CFSE-





Figure 2.3: Optimization of suppression analyses for MSC and splenocyte co-culture 




 splenocytes, and 
stained with CFSE at the initiation of co-culture. Unstimulated co-cultures were used as gating controls. (A) Gating for 
proliferation analysis. Stimulated splenocytes were gated based on size to include both blasting and quiescent cells, as seen in 
the top panel. This lymphocyte gate was isolated and the CFSE signal for both the unstimulated and the unstained cells (middle 
and bottom panels) were viewed. A “divided cells” gate was created based on these histograms to determine the percent 
divided. (B) Gates created in part A of this figure were subsequently applied to all samples in the experiments. The panels here 
are representative histograms of some samples in these analyses with the appropriate gates, and labeled for the amount of 
unsorted, irradiated MSCs that were placed in the co-culture. The percentages were tabulated for comparison. (C) Suppression 
of CD3
+
 T-cells by unsorted MSCs, analyzed every 24 hours. Data are indicated as percent divided, +/- standard error. 
 
Effect of CD105 Expression on T-cell Proliferation 
 There have been several studies that observed the effect of MSCs on the proliferation of CD4+ 
and CD8+ T-cells.93 Some have even documented the anti-proliferative effect as a function of CD105 
expression.3 However, few have investigated whether the syngeneic or allogeneic source of T-cells can 
be a determining factor for the efficacy of suppression by MSCs with respect to the expression of CD105. 
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MSCs with the expression profile CD90+, Sca-1+, CD45- c-kit- were sorted based on CD105 positivity and 
placed in the previously described transwell co-culture system, after they were irradiated. A population 
that was unsorted for CD105 was also irradiated and placed in this system.  
 Splenocytes were isolated from either C57BL/6J or C3H/HeJ mice and sorted for CD4 or CD8 
expression. Following CFSE staining, they were placed in stimulation cultures with the 3 MSC treatment 
groups in transwell inserts. The ratio of MSCs to CD4+ or CD8+ cells was 1 MSC for every 5 T-cells. 
Controls for this experiment included CFSE-stained T-cell stimulation cultures without MSCs, CFSE-
stained T-cells without stimulation, and unstained, stimulated T-cells. CFSE-signals were obtained after 
48 hours, and analyzed with the same method found in Figure 2.3A/B. 
 The results from these experiments can be found in Figure 2.4. The CD4+ populations 
demonstrated very slight suppression compared to the non-MSC stimulated controls, as seen in Figure 
2.4A. The CD105- suppression culture showed the most suppression at 73.79%±1.21 and 75.57%±1.23 
for syngeneic and allogeneic, respectively. This compares to the 76.45%±1.41 for the syngeneic group 
and 78.05%±1.61 for the allogeneic group without MSCs. The CD105+ populations produced less 
suppression than either the unsorted MSC or the CD105- groups in these CD4+ co-cultures. No significant 
differences were found across all experimental groups.  
 A similar pattern held true for the CD8+ cells in the syngeneic model, with CD105- cells producing 
the greatest suppression effect of 81.86%±3.35 divided cells compared to 85.69%±2.01 divided cells in 
the non-MSC containing, stimulated control. In contrast, an unexpected observation emerged for the 
CD8+ allogeneic co-culture assays. Co-culture with all MSC groups produced a slight stimulation effect 
compared to controls. The least stimulatory effect was seen in the CD105- group, with the unsorted and 
CD105+ populations creating more divided cells. With both patterns in the syngeneic and allogeneic CD8 















unsorted MSCs. Percent of divided cells was calculated 48 hours after incubation with MSC subgroups. Data are presented as 
percent-divided, +/- standard error. (A) CD4
+
 splenocytes were sorted from C57BL/6J mice for a syngeneic co-culture (left) and 
C3H/HeJ mice for an allogeneic co-culture (right). Both co-cultures produced a very slight suppression, with CD105
-
 MSCs 
suppressing at 73.79%±1.21 and 75.57%±1.23 for syngeneic and allogeneic, respectively. (B) CD8
+
 splenocytes were sorted from 
C57BL/6J mice for a syngeneic co-culture (left) and C3H/HeJ mice for an allogeneic co-culture (right). The syngeneic model also 
produced a slight suppression, with the most seen in the CD105
-
 group (81.86%±3.35). However, there was a stimulation effect 
seen in the CD8
+
 allogeneic model, with each MSC co-culture group producing a slight increase in percent divided cells.  
 
Characterization of Differentiated Syngeneic CD4+ Cells  
 To address the question of how the presence of CD105 on MSCs influences the differentiation of 
CD4+ T-cells, CD4+ splenocytes were isolated from C57BL/6J mice for a syngeneic model. These sorted 
CD4+ populations were placed in stimulated co-cultures with or without CD105+/- MSCs and allowed to 
expand for 72 hours. The cultures were then refreshed and restimulated without their corresponding 
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experimental MSC-groups, and allowed to proliferate for 24 hours. The mRNA was harvested from these 
differentiated CD4+ populations and subjected to quantification analyses for the identification of 
different T-cell phenotypes.  
 In Figure 2.5A, the constellation of GATA-binding protein 3 (GATA3), IL-4, and IL-5 test the 
relative amounts of these Th2-associated factors. GATA3 is a transcription factor which controls 
expression of both IL-4 and IL-5, and helps induce Th0 cells to a Th2 phenotype.94 In these expression 
assays, the CD105+ MSCs produced greater fold-changes than their CD105- counterparts. Interestingly, 
the IL-5 expression demonstrated a significant overall downregulation when compared to non-co-
cultured (NCC) controls for the CD105- group. This differs from the upregulation seen in the CD105+ 
cultures. The mRNA production between the NCC controls and the MSC-co-cultures reached a high level 
of significance (p<0.005) for the CD105- effect of downregulation in IL-5. The upregulation of GATA3 and 
IL-4 was significant when compared to NCC controls for the CD105+ co-cultures only. 
 Factors associated with T-regulatory (Treg)-function are depicted in Figure 2.5B. There are 
minimal and non-significant differences for forkhead box P3 (FoxP3). The production of IL-10 is 
significantly increased for CD105+ MSC-culture conditions compared to NCC controls. However, CD105- 
MSCs did demonstrate a higher numeric fold-change in comparison to the CD105+ MSCs. 
 Figure 2.5C compares the pro-inflammatory, Th17-associated factors after differentiation 
cultures. Th17 cells have been associated with the suppression of the Treg phenotype,95 and play an 
important role in maintaining an antimicrobial environment in mucosal barriers.96 Aberrant Th17 
induction has also been associated with autoimmune disease.97 Additionally, Th17 cells require small 
amounts of TGF1 to differentiate,98 which make their subset an interesting target for study in the 
context of CD105+/- co-culture.  CD105- MSCs produced less Th17-associated transcription than the 
CD105+ cells for each of the examined factors. However, Interleukin-17a (IL-17a), the hallmark cytokine 
of Th17 cells, shows significant downregulation in both MSC-co-culture groups compared to NCC 
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controls (p<0.005). In the examination of retinoid-related orphan receptor-γ (RORC), it is clear that both 
MSC culture groups upregulate its expression, but it is not significant for the CD105- MSC co-cultures.  In 
Interleukin-22 (IL-22), a different pattern emerges, where the CD105- group comparatively produces a 
decrease in expression, but CD105+ upregulates this cytokine.  The reduction of IL-22 as influenced by 
CD105- MSCs reaches statistical significance (p<0.005) when compared to NCC controls. 
 Other pro-inflammatory cytokines and transcription factors associated with Th1 and  T-cells99 
were analyzed, the results of which can be found in Figure 2.5D. Interleukin-23 receptor (IL-23R) is also 
associated with the Th17 phenotype. Its presence has been conversely linked with T-box transcription 
factor 21 (Tbx21) and IFN for determining if naïve CD4+ T-cells differentiate into a Th1 or Th17 
functional T-cell.99 All of the Th1/ T-cell associated factors examined had numerically greater fold-
changes in the CD105+ co-culture assays compared to the CD105-, though these comparisons did not 
reach significance. IL-23R shows mild, non-statistically significant upregulation for both groups of MSCs 
in this syngeneic context. Tbx21 is a distinct Th1 transcription factor, which controls the expression of 
IFN.100 MSC-co-cultures did upregulate Tbx21 to some degree, but predictably, the results were not 
statistically significant when compared to NCC controls. IFN, however, was consistently downregulated 
in all MSC-co-cultures. These results reached significance when compared to the NCC group (p<0.05).  




Figure 2.5: Differentiation of CD4
+
-splenocytes after co-culture with syngeneic CD105
+/-
 MSCs 
Values are represented as means±SEM. (A) Comparison of transcription factors associated with the promotion of a Th2 
phenotype after differentiation cultures. The CD4
+
 T-cells co-cultured with CD105
-
 MSCs demonstrated a slight decrease in 
these factors, but these did not reach significance. The syngeneic CD105
-
 groups produced a fold-change of 1.28±0.17 and 
0.517±0.12 for IL-4 and IL-5, respectively. (B) Comparison of Treg associated transcription factors after differentiation cultures. 
No significant changes were found in the regulation of FoxP3. However, each co-culture condition upregulated the expression 
of IL-10, with the CD105
-
 co-culture having a higher 2.14±0.71-fold change compared to the 1.91+0.35-fold change for the 
CD105
+
 group. (C) Comparison of pro-inflammatory, Th17-associated factors after differentiation cultures. IL-17a was 
downregulated by both co-culture conditions, with CD105
-
 MSCs producing a more pronounced reduction in fold change by 
0.26±.07 compared to the CD105
+
, which reduced the expression by 0.46±0.09-fold. While both co-culture conditions did 
upregulate the expression of RORC, the CD105
+
 group’s expression was greater at 1.59±0.25-fold compared to CD105
-
, 
producing only a 1.26±0.39-fold increase. The CD105
-
 group had a more dramatic downregulation in expression for IL-22 at 
0.43±0.13-fold compared to controls, while the CD105
+
 co-culture group upregulated IL-22 slightly at 1.15±0.34. (D) 
Comparison of Th1-associated proinflammatory factors after differentiation culture. While IFN expression was suppressed by 
both co-cultures (0.74±0.09 for CD105
+
 and 0.57±0.16 for CD105
-
), IFN’s controlling transcription factor: Tbx21, was 
upregulated. CD105
-
 co-cultures did produce less expression of Tbx21 than their CD105
+
 correlating co-cultures, however 
(1.35±0.54 and 1.52±0.35-fold, respectively). IL-23R also demonstrated upregulation, in a similar pattern with respect to co-
culture conditions. None of these results reached statistical significance. indicates that the fold-change is significant compared 







Table 2.1: Summary of syngeneic expression changes relative to NCC controls. 
These are the data from CD4
+
 C57BL/6-derived splenocytes co-cultured with CD105
+/-
 MSCs that were assayed for 






























Cytokine Production by Differentiated Syngeneic Co-Culture Products 
 From these same differentiation assays, the supernatants were simultaneously harvested. The 
fresh supernatant was then subjected to a Th1/Th2 ELISA characterization assay, wherein the factors 
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IFN, IL-2, IL-4 and IL-10 were quantified in each of the different experimental groups. For the Th2-
cytokines IL-4 and IL-10, the expected pattern emerged in a most significant fashion. As visible in Figure 
2.6A, experimental groups that were co-cultured with MSCs produced a greater amount of IL-4 than the 
NCC controls. The CD105- groups produced significantly more IL-4 than their CD105+ counterparts in this 
syngeneic context. CD105- cultures also produced more IL-4 than the NCC controls in a significant 
fashion. This correlation was predicted by the mRNA expression data. 
 A nearly identical pattern also emerged for the production of IL-10 by these differentiated CD4+ 
cells (Figure 2.6B). CD105- co-cultures produced more IL-10 than their CD105+ correlates, the differences 
reaching statistical significance. In fact, this syngeneic CD105+ group actually produced less IL-10 than 
the stimulated NCC controls, though these differences did not reach significance (p=0.28). Despite this 
minor discrepancy, the CD105- MSC co-cultures appear to shift the differentiation of these CD4+ 
splenocytes to the more tolerant Th2 phenotype more efficiently than their CD105+ correlates. 
 The expression of IL-2 was quantified from these same differentiated cultures using the ELISA 
assay described. In Figure 2.6C, the comparative concentrations for these co-cultures can be examined. 
The CD105+ co-cultured cells followed a different pattern than would be predicted for a Th2-associated 
type. While both syngeneic cultures produced less IL-2 than the NCC controls, The CD105+ syngeneic 
culture did not create as much IL-2 as the CD105- correlates. These did not reach statistical significance. 
 Interestingly, for the quantification of IFN in Figure 2.6D, there were divergent patterns from 
the anticipated production in these syngeneic populations: both syngeneic MSC-co-cultures produced 
more IFN than the NCC controls. This pattern was unanticipated as compared to the NCC controls, but 
the expression of CD105 as a factor for determining IFN production was predicted by the expression 





Figure 2.6: Differences in cytokine production by co-cultured syngeneic CD4
+
 T-cells after 24 hour restimulation 
Values represented as means±SEM. (A) IL-4 Production: In the syngeneic context, CD105
+
 MSCs produced significantly less IL-4 
(288.01±34.49pg/mL) compared to their CD105
-
 counterparts (476.16+35.80pg/mL) (p<0.01). Differences between the MSC-
cohort and the cohort without MSCs (187.60±78.23pg/mL) only reached significance in comparison to the CD105
- 
co-culture 
group. However, there were numeric differences between the average concentration of the CD105
+
 groups and the group 
without MSCs. The higher standard deviation within the non-co-cultured (NCC) syngeneic group could account for the lack of 
statistically significant differences between NCC controls and all MSC-containing co-cultures. (B) IL-10 Secretion: Within the 
syngeneic group, CD105
+
 MSCs produced significantly less IL-10 (1675.21L±98.69pg/mL) compared to their CD105
-
 counterparts 
(3237.29±458.95pg/mL) (p<0.02). Differences between the MSC-cohort and the NCC cohort (3166.88±1278.35pg/mL) did not 
have significant differences in IL-10 production. However, this may be due to the high standard deviation of the differentiated 
CD4
+
 T-cells that were in the NCC group. (C) IL-2 Production: The syngeneic CD105
+
 group demonstrated less IL-2 production 
(12740.9±2055.79pg/mL) than their CD105
-
 counterparts (14385.15±729.06pg/mL), though this did not reach statistical 
significance. While both MSC-containing syngeneic groups did produce less IL-2 than the NCC controls, these results also did not 
reach statistical significance. This could, in part, be due to the high standard deviation of NCC group. (22425.9±9211.10pg/mL). 
(D) Quantification of IFN: Both CD105
-
 co-cultures produced less than their CD105
+
 correlates in both the syngeneic and 
allogeneic context, with 38194.49±2771.01pg/mL for the syngeneic CD105
+
 and 36363.60±2953.92pg/mL for CD105
-
 co-
cultures. Surprisingly, all co-cultures resulted in increased IFN production when compared to their NCC controls, with only 
26279.04±10260.43pg/mL produced from the C57BL6/J derived T-cells. (n=4) 
 
Characterization of Differentiated Allogeneic CD4+ Cells  
 The characterization of syngeneic CD4+ differentiation in the presence of CD105+/- MSCs was 
distinctly novel. However, to address the role of allogeneic factors in this newly documented 
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immunomodulation, the same assays described above were repeated using splenocytes from C3H/HeJ 
mice. Surprisingly, they produced significant differences for several of the factors examined. In Figure 
2.7, the results of the mRNA quantification and analysis can be found.  
 Figure 2.7A displays the data for Th2-associated factors created by the differentiated 
splenocytes. Here, the pattern observed in the syngeneic model is reversed, where CD105- MSC co-
cultures creates a numerically higher upregulation of the Th2-associated factors. With the exception of 
IL-5, these allogeneic CD105- co-cultures produced more Th2-indicative cytokines than their CD105+ 
counterparts, but these did not reach significance. Additionally, the CD105- co-cultures consistently and 
dramatically produced statistically significant variation from the NCC controls (p<0.05 and p<0.005). This 
suggests that the Th2 phenotype is more pronounced in the allogeneic co-cultures, particularly in the 
absence of CD105 expression on the MSCs. In these expression assays, the allogeneic co-culture group 
also produced consistently higher numeric upregulation in the fold changes of these Th2-promoting 
factors compared with their syngeneic counterparts. 
 Unlike the cells gathered from the syngeneic co-cultures, the CD105- allogeneic cells had 
statistically significant differentiation toward a Treg phenotype (Figure 2.7B), as indicated by the slight 
upregulation of FoxP3 (p<0.05). While the pattern of IL-10 production is consistent between syngeneic 
and allogeneic models, IL-10 expression is increased in the CD105- allogeneic context compared to the 
syngeneic. Additionally, the allogeneic upregulation of IL-10 reached statistical significance in both MSC 
co-culture groups compared to NCC controls (p<0.005). Since IL-10 is also a Th2-associated factor,101 it is 
unsurprising that this pattern is similar to those for IL-4.  
 The data for Th17-associated factors can be found in Figure 2.7C. The allogeneic co-cultures 
downregulated expression of all Th17-associated factors. In the examination of RORC and IL-22, a 
different pattern emerges, where the CD105- allogeneic group comparatively produces the greatest 
decrease in expression. The allogeneic CD105+/- comparisons only reached significance for the 
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downregulation of IL-22. IL-22 is the only factor that had a compounding, statistically significant 
variation from the NCC controls in their downregulation for both MSC co-culture groups (p<0.005). 
Comparisons of IL-17a expression show a different pattern in this allogeneic analysis. While the 
allogeneic CD105+ cells express the IL-17a mRNA to a lesser extent than the CD105- cells, neither of 
these values reached significance compared to NCC controls. These differences did become significant, 
however, between the CD105- syngeneic and allogeneic co-cultures.  
 As seen with the Th17 panel in Figure 2.7C, IL-23R shows downregulation in the allogeneic 
cultures compared to upregulation in the syngeneic context. Expression levels were similar in 
comparison of the CD105+/- co-cultures for IL-23R, with differing levels that did not reach significance. 
While all MSC-co-cultures did upregulate Tbx21 to some degree, it did not follow a pattern that was 
consistent with any other factor examined. IFN, however, was consistently downregulated in all MSC-
co-cultures. The allogeneic groups produced the most downregulation, though there was no correlation 
with CD105+/- between syngeneic and allogeneic cultures. These results only reached significance in their 
comparison of IFNproduction from the NCC controls (p<0.05). A summary table of this information 





Figure 2.7: Differentiation of CD4
+
-splenocytes after co-culture with allogeneic CD105
+/-
 MSCs 
Values are represented as means±SEM. (A) Comparison of transcription factors associated with the promotion of a Th2 
phenotype after differentiation cultures. All of the MSC co-culture groups produced more Th2-associated factors when 
normalized to controls. With the exception of IL-5, the CD105
-
 group demonstrated a slight increase in these factors compared 
to their CD105
+
 counterparts, but these did not reach significance. The CD105
- 
co-culture produced an upregulating effect for IL-
4 and IL-5 by 2.34±0.19 and 2.37±0.26, respectively. This suggests that the Th2 phenotype is more pronounced in these 
allogeneic co-cultures, particularly in the absence of CD105 expression on the MSCs. (B) Comparison of Treg-associated 
transcription factors after differentiation cultures. Slight upregulation of FoxP3 was found to be significant in CD105
-
 co-cultures 
(p<0.05). However, each co-culture condition upregulated the expression of IL-10. The greatest effect was seen in the 
allogeneic CD105
-
 group (4.20±0.71-fold change) which had a statistically significant difference from the syngeneic CD105
-
 co-
culture (2.14±0.71-fold change) (p<0.005). (C) Comparison of pro-inflammatory, Th17-associated factors after differentiation 
cultures. All allogeneic co-cultures downregulated the expression of each Th17-associated factor. Statistically significant 
differences in IL-17a were seen between the CD105
-
 syngeneic and allogeneic co-cultures, both downregulating by 0.26±.07 and 
0.94±0.27-fold, respectively (p<0.05). For IL-22 and RORC, a different pattern emerges, where the CD105
- 
allogeneic group 
comparatively produces the greatest decrease in expression (0.24±.05-fold and 0.81±0.15-fold, respectively). The allogeneic 
CD105
+/-
 comparisons only reached significance for the downregulation of IL-22 (p<0.005). (D) Comparison of Th1-associated 
proinflammatory factors after differentiation culture. For both IL-23R and IFN, a pattern of downregulation for both co-
cultures is apparent. While IFNwas suppressed by all co-cultures, Tbx21 (which controls IFN expression) was upregulated. 
None of these results reached statistical significance. The CD105
-
 culture group produced slight increases in expression for each 
of the Th1-associated factors, but none of these reach significance. indicates that the fold-change is significant compared to 









Table 2.2: Summary of allogeneic expression changes relative to NCC controls. 
These are the data from co-cultured CD4+ C3H/HeJ-derived splenocytes with CD105+/- MSCs and assayed 






























Cytokine Production by Differentiated Syngeneic Co-Culture Products 
 Performed in an identical fashion to the secreted cytokine assay above, the fresh supernatant 
from the allogeneic differentiation assays was subjected to a Th1/Th2 ELISA characterization 
experiment, wherein the factors IFN, IL-2, IL-4 and IL-10 were quantified in the control and 
experimental groups. For the Th2-cytokines IL-4 and IL-10, the same pattern emerged that was 
54 
 
ascertained from the data of the syngeneic group. However, these results were significantly more 
dramatic than their syngeneic CD105+/- correlates (p<0.005 between CD105+ syngeneic and allogeneic, 
and p<0.05 for CD105-).  As visible in Figure 2.8A, all experimental groups that were co-cultured with 
MSCs produced a greater amount of IL-4 than the stimulated controls. Both CD105+/- allogeneic co-
cultures produced significantly more IL-4 than the NCC controls.  This correlation was predicted by the 
mRNA expression data. 
 A similar pattern became apparent for the production of IL-10 by these differentiated CD4+ cells 
(Figure 2.8B). However, the production of IL-10 by the allogeneic group is more dramatic than their 
syngeneic counterparts (p<0.005). Allogeneic CD105- co-cultures produced more IL-10 than their CD105+ 
correlates, but these did not reach significance. Both allogeneic groups produced significantly more IL-10 
than the NCC controls (p<0.05 for CD105+ and p<0.005 for CD105-). CD105- MSC co-cultures appear to 
shift the differentiation of these CD4+ splenocytes to the more tolerant Th2 phenotype more efficiently 
than their CD105+ correlates: an effect that is most consistent in the allogeneic context.  
 In Figure 2.8C, the comparative concentrations of IL-2 produced from these co-cultures can be 
examined. The CD105+ co-cultured cells in both syngeneic and allogeneic groups followed a different 
pattern than would be predicted for a Th2-associated type. In the allogeneic setting, the CD105+ co-
cultured cells exuded significantly more IL-2 than any other population, including the NCC controls. The 
allogeneic CD105- co-cultured cells, however, did follow the expected pattern of producing less IL-2 than 
all other co-culture groups, though this did not reach significance.  
 For the quantification of IFN in Figure 2.8D, there were patterns similar to the syngeneic group 
surrounding CD105 expression, namely: the absence of CD105 correlated with a decreased production 
of IFN in this allogeneic setting.  The allogeneic CD105+ co-cultures also produced significantly more 
IFN than their syngeneic correlates (p<0.05). Here, differences between secreted IFN from the CD105+ 
co-cultures and the NCC controls from C3H/HeJ mice reached significance. This pattern was 
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unanticipated as compared to the NCC controls, but the expression of CD105 as a factor for determining 
IFN production was predicted by the expression analyses documented in Figure 2.7D.  
 
Figure 2.8: Quantification of cytokine production by CD4
+




Values represented as means±SEM. (A) IL-4 Production: the allogeneic co-cultures did not display significant differences in IL-4 




 cohorts, though the amount from the CD105
-
 co-culture contained a higher 
numeric average of produced IL-4 (767.94±63.83pg/mL)  than the CD105
+
 (725.44±53.58pg/mL) group. However, both MSC-co-
cultured groups created significantly more IL-4 production than the corresponding syngeneic groups (p<0.01). Additionally, 
both allogeneic co-cultures produced significantly more IL-4 than their counterparts without MSCs (101.12±31.52pg/mL) 




 cohorts. However, both 
MSC-co-cultured groups created significantly more IL-10 than the corresponding syngeneic groups, with 




 co-culture groups, respectively (p<0.0005). 
Additionally, both allogeneic co-cultures produced significantly more IL-10 than their counterparts without MSCs 





(7357.3±2492.81pg/mL) co-cultures were found (p<0.001). The CD105
+
 allogeneic 
cohort, surprisingly, produced significantly more IL-2 than the cultures that were not incubated with MSCs 
(1355.35±5020.49pg/mL) (p<0.05). Comparison of the syngeneic and allogeneic groups for CD105
+/- 
expression did yield 
significant differences (p<0.001 and p<0.05, respectively). (D) Quantification of IFN: allogeneic co-cultures produced more 





, respectively. These values reached statistical significance in the CD105
+
 syngeneic vs. allogeneic 
comparison (p<0.05). All co-cultures resulted in increased IFNproduction when compared to their NCC controls, with only 
19587.28±7671.95pg/mL produced from differentiated CD4
+
 T-cells from C3H/HeJ mice. These values only reached significance 
between the allogeneic CD105
+





 The syngeneic T-cell suppression models that this study sought to replicate and apply in an 
allogeneic context for examining the effect of CD105 expression on MSCs were performed by Anderson 
et al. 3 The previous model, however, had some methodological differences that could potentially 
explain the inconsistencies in our results. In the previous studies, the greatest concentration of CD105+/- 
MSCs was plated at a ratio of 1 MSC for every 40 splenocytes. Despite this, they were able to produce a 
significant reduction in their proliferation index. However, these studies used only anti-CD3 at a low 
concentration of 1g/mL for stimulation in the soluble phase. The methods described in our study were 
unable to produce stimulation without both anti-CD3 and anti-CD28 being plate-bound (Figure 2.1). 
Since the proliferative index is calculated based upon a control group which lacks the experimental 
variable to suppress proliferation (in these cases, MSCs), perhaps the reported values in the previous 
study are, in fact, comparable to the percent-divided that were reported in this study. However, the 
dose-response was still inconsistent. Alternatively, the induction of proliferation used in this study could 
potentially have overcome the suppressive effect of our MSC dosage. Some groups have even reported 
a necessary 100:1 ratio of MSCs:T-cells in order to suppress growth.102 
 One very interesting finding of this study is the seemingly stimulatory effect of all MSC-groups 
upon the allogeneic CD8+ T-cell population. MSCs have been shown previously, even in an allogeneic 
system, to produce inhibition of CD8+ cell proliferation.103 However, this group performed their assays 
on APC-primed and antigen-specific CD8+ T-cell lines, and concluded that MSCs inhibited proliferation by 
hampering interactions with antigen-presenting cells. Since this study did not make use of antigen-
presenting cells, and used primary T-cells that had not previously been stimulated and maintained in 
culture, these results are difficult to directly compare.  
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 An alternative idea that might explain the slight stimulation in our CD8+ T-cells is this: the MSCs 
in these allogeneic cultures are promoting the growth of a specific, modulatory type of CD8+ t-regulatory 
cell, with the CD8+CD28- phenotype. Liu et al published findings that purified CD3+CD8+ T-cells had a 
greater proportion of CD8+CD28- cells after co-culture with MSCs.104 These CD8+CD28- T-cells have 
shown the capacity to inhibit the proliferation-activated CD4+ T-cell populations in co-culture.105 
Therefore, it is possible that this CD8+CD28- population has been so enhanced in co-culture with the 
MSCs, that it actually is seen as having a proliferative effect on the overall CD8+ co-culture. 
 The lack of statistically significant differences between CD105+ and CD105- groups could 
therefore be explained by the fact that our assays were performed specifically on CD4+ or CD8+ T-cells. 
The differentiation effects of MSCs in a mixed-splenocyte reaction have been shown to increase the 
proportion of regulatory T-cell phenotypes,106 and these cells could, in turn, decrease the overall 
proliferation of the mixed splenocytes via inhibitory cytokines. 
 These results have demonstrated that there are significant differences between syngeneic and 
allogeneic MSC-based differentiation cultures of CD4+ T-cells. Additionally, some of these effects can be 
correlated to the expression of CD105 on the MSCs in co-culture. The expression data from these co-
cultures suggest that the allogeneic setting induces the transcription of more Th2-associated factors, 
such as GATA3, IL-4, IL-5, and IL-10. Additionally, there were consistent differences seen in the 
allogeneic CD105- co-culture groups for GATA3, IL-4, and IL-10, which showed increased transcription of 
these factors compared to their CD105+ counterparts. However, there were no significant differences or 
patterns detected in the FoxP3 expression, suggesting that the function of Treg cells and their 
suppression of Th1/Th17 subtypes95 were not indirectly involved in the promotion of the Th2 population 
by means of depleting the other populations. It can therefore be concluded that MSCs themselves, in 
the allogeneic context, provide a mechanism for promotion of the Th2-phenotype, either by increasing 
the proportion of these cells directly or by suppressing the growth of Th1/Th17 populations. This is 
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perhaps a necessary mechanism for self-preservation, by inducing immune-tolerance in these allogeneic 
settings. 
 However, while there were differences between CD105+/- syngeneic and allogeneic co-cultures 
in the Th1 and Th17 expression panels, the pattern was inconsistent in its specific suppression of these 
subtypes. These factors were not expressed conversely from the Th2-associated factors, which would 
have indicated a promotion Th2-development by depletion of other Th-types. However, IL-17a, IL-22, 
IL23R and IFN were all downregulated in the allogeneic co-cultures, but there was no correlation in 
downregulation with the expression of CD105. 
 To elucidate the significance of the expression data in terms of actual T-cell functionality, the 
quantification of secreted proteins by the differentiated CD4+ cells was characterized using a Th1/Th2 
panel. The results seen in Figure 2.6A for IL-4 production was predicted by, and correlated with, the 
expression data. IL-10 production also correlated precisely with the expression data in both the 
syngeneic and allogeneic context. For both IL-4 and IL-10 production, however, the higher standard 
deviation within the NCC-syngeneic group could account for the lack of statistically significant 
differences between it and all MSC-containing co-cultures, like those seen in the allogeneic group. 
 The Th1-cytokine production patterns do not correlate with the expression data. In fact, all MSC-
cultures appeared to induce the expression of IFN, the hallmark Th1 cytokine.107  While the CD105- co-
cultures for both syngeneic and allogeneic produced less IFN than their CD105+ correlates, the results 
did not reach significance. The lack of CD105 also proved important for IL-2 reduction in the allogeneic 
context, but the opposite was true in the syngeneic setting. The production of IL-2 was less in these 
syngeneic MSC-groups compared to NCC controls, but here, CD105- demonstrated a greater 
concentration of IL-2 than the CD105+ co-cultures. The higher standard deviation seen in the Th1-
cytokine production by the NCC controls could account for some of the variability in these data. 
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 Perhaps the existence of other Th-subtypes in the differentiation cultures could explain the Th1-
associated cytokine-production. Namely, why it does not exhibit the converse patterns created by 
allotypes and CD105 expression in theTh2-cytokine panels. There has been documented compensatory 
reactions between Th17 and Th1 subtypes, which show the depletion of one group leads to increased 
production of the other.108 Additionally, it is highly improbable that every CD4+ cell was differentiated 
toward one, specific Th-lineage, and the Th1-cells that remain in these differentiation assays could be 











Figure 2.S2.9: Schematic of experimental co-culture designs with MSCs and various splenocyte 
populations. 
 
Table 2.S2.3 qPCR Primer Sequences for Differentiation Assay. All primers are species-specific to 
murine cDNA libraries 
Factor Forward (5'->3') Reverse (5' -> 3') 
HPRT GGC CAG ACT TTG TTG GAT TTG  CGC TCA TCT TAG GCT TTG TAT TTG  
IFN GGC CAT CAG CAA CAA CAT AAG GTT GAC CTC AAA CTT GGC AAT AC  
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IL-17a CGC AAT GAA GAC CCT GAT AGA T  CTC TTG CTG GAT GAG AAC AGA A 
IL-22 CGA CCA GAA CAT CCA GAA GAA GAG ACA TAA ACA GCA GGT CCA 
IL-23R GAG CCA GAC AGC AAG TAT GT  CAG TTT CTT GGG AAG TTT GGT G 
IL-4 GAA GAA CAC CAC AGA GAG TGA G TGC AGC TCC ATG AGA ACA C 
IL-5 CCC AAC CTT AGC ATC CTT TCT AGG GAG TTG AGG AGA GAT TGA  
IL-10 TGC ACT ACC AAA GCC ACA A GAT CCT CAT GCC AGT CAG TAA G 
RORC  ATC TGG AGG AAG GAC AAC TTT C CCT AGG GAT ACC ACC CTT CAT A  
Tbx21 CCA GGG AAC CGC TTA TAT GT CCT TGT TGT TGG TGA GCT TTA G 
FoxP3 CCC AGT GCC CAT CCA ATA AA TTC TCC TGC TGG GAT CTT AAA C 




Chapter 3: Impact on Hyperbaric Oxygen on Post-UCB Transplant Transfusion 





 Limitations in umbilical cord blood (UCB) transplantations originate from decreased cell 
numbers available for infusion at time of transplant. Delayed engraftment and higher rates of 
engraftment failure subsequently increase the need for post-transplant transfusion support. Hyperbaric 
oxygen (HBO) has been shown to improve engraftment in an animal model of UCB transplantation, and 
these experiments proved sufficient to initiate a first-in-human trial of HBO for UCB transplantation.  
 This study seeks to evaluate time to packed red blood cell (PRBC) and platelet independence for 
the HBO study population, and compare to retroactively reviewed UCB transplant data from the same 
institution. Additionally, it seeks to compare the effects of conditioning regimens, and the number of 
cord units infused at time of transplant for transfusion independence.  
 Fifteen subjects underwent HBO therapy at the University of Kansas Cancer Center after 
reduced intensity conditioning (RIC) (n=9) or myeloablative conditioning (MAC) (n=6) regimens.  6 hours 
following therapy, they received single (n=8) or double (n=7) UCB units. The patient charts were 
reviewed for post-transplant PRBC and platelet transfusion requirements. These were compared to 
standard cord-blood recipient requirements from previous KUCC patients. These were further evaluated 
between preparative regimens and number of UCB units infused.  
 Patients who experienced relapse of disease or who expired during the first 100 days were 
excluded from the quantification of PRBC and platelet unit analyses. They were, however, evaluated to 
determine if transfusion independence had been reached prior to these events, and included if this was 
demonstrated in their records.  
 In the first 100 days, there were no significant differences found in the units of PRBC and 
platelets required for transfusion support between the HBO and standard groups. The consecutive days 
of neupogen support post-transplant were consistently fewer for the HBO patients, including analyses 
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segregated by regimen and number of cords infused. Most significantly, the HBO-group had drastically 
shorter times to both PRBC and platelet independence. In fact, by days 66 and 74 post-transplant, 100% 
of HBO-patients were PRBC and platelet independent, respectively. This compares to incomplete 
platelet (88.63%) and PRBC (86.36%) independence in their standard-transplant counterparts at day 
100. While these did not reach statistical significance, it is most likely due to small sample size of the 
HBO-cohort and their subdivisions. For mechanistic purposes, the HBO-cohort had their erythropoietin 
levels assessed 8 hours after the HBO-therapy. At present, there has not been a definitive clinical 
correlation between EPO levels, transfusion requirements, or transfusion independence. The findings 
demonstrate a previously described increase in EPO levels with myeloablative therapy in contrast to a 






 The use of umbilical cord blood (UCB) for allogeneic hematopoietic stem/progenitor cell (HSPC) 
transplant has been beneficial for groups that had previously faced limitations based on HLA-
requirements, such as racial and ethnic minorities.109 Clinically, UCB is also associated with a lower 
incidence of GVHD despite HLA disparity for the recipient.110  However, there has been documentation of 
higher rates of engraftment failure for UCB-recipients compared with the recipients of HLA-matched 
bone-marrow (BM). Patients also have been documented to experience delayed neutrophil and platelet 
engraftment, complicating the post-transplant course with higher rates of infection and emergent 
transfusions.111  This has correlated, and therefore been associated with, decreased numbers of 
nucleated cells available for transplant in the case of UCB. 110, 112, 113 To resolve this, several groups have 
focused on the expansion of UCB-HSPCs ex-vivo and studying mechanisms of BM-homing.114 It has been 
noted that a population of repopulating HSPCs loses its in vivo capacity when cultured briefly with 
stimulatory cytokines.115 This has held true for HSPCs of different origins, including UCB-derived HSPCs in 
a NOD/SCID mouse model.116  
 Therefore, it would perhaps be more clinically useful to enhance the homing of the HSPCs, such 
that the lower starting numbers available in UCB would translate to a higher probability of engraftment 
in vivo. The mechanism of BM-homing for CD34+ HSPCs has been extensively studied, but remains 
elusive in many aspects. It has been proposed that the expression of cell-surface molecules, including 
very late antigen (VLA)-4, VLA-5, C-X-C Motif Chemokine Receptor (CXCR)4, and B2-integrins expressed 
on CD34+ cells, are important for interacting with marrow stromal cells to increase homing in the 
hematopoietic niche.115 The maintenance of this specific CD34+ phenotype is therefore important to 
ensure that transplanted cells reach their destination in the host marrow.  
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 Erythropoietin (EPO) is an endogenous factor that has demonstrated the capacity to influence 
HSPC growth and differentiation toward an erythroid lineage.117 In neonatal studies, circulating HSPCs 
decline in a manner that correlates with lower serum EPO concentration.118 It was therefore 
hypothesized in our previous studies that EPO exposure causes changes in the homing capacity of 
HSPCs.  We proved that there was a decrease in stromal-cell derived factor 1 (SDF-1)-driven migration of 
UCB-CD34+ HSPCs when the EPO/EPO-receptor signaling pathway was induced. This was rescued by the 
inhibition of the EPO/EPOR signaling pathway.119 
 Since Hyperbaric Oxygen (HBO) has proven to decrease circulating levels of EPO in healthy 
subjects,120 HBO was employed to induce an in vivo murine model for the reduction of EPO signaling in 
UCB-transplant.  This demonstrated that myeloid, B-cell, and T-cell engraftment is enhanced compared 
to control mice. There were differences in early kinetics of UCB-CD34+ cell distribution.121 
 These data were sufficient to conduct a first-in-human trial of HBO treatment for patients 
undergoing UCB-HSPC transplant. The primary aims were for evaluating the safety of HBO in the context 
of treatment for HSPC transplant, with secondary aims for efficacy to compare rates of engraftment and 
blood count recovery. This study is a comparison of the requisite transfusion support for these patients 






 The study was approved by the institutional review board at the University of Kansas Medical 
Center (KUMC) prior to initiation, and was registered at clinicaltrials.gov (NCT02099266). At the 
University of Kansas Cancer Center, fifteen patients with acute myeloid leukemia (AML) or acute 
lymphoblastic leukemia (ALL) who required HSPC transplant were consented according to Human-
Subject Committee approved study number 13601 to undergo hyperbaric oxygen treatment. Given the 
increased risk for pulmonary complications in patients with severe pulmonary disease undergoing HBO, 
patients were excluded if they had a history of severe COPD or history of spontaneous pneumothorax.  
Hyperbaric Oxygen Treatment 
 After a signed written consent, patients in the HBO-cohort were subjected to 2 hours of 100% 
oxygen at 2.5 ATM following their reduced intensity conditioning (RIC) (n=9) or myeloablative 
conditioning (MAC) (n=6) regimens. Patients rested during this time in a supine position in the 
transparent hyperbaric chamber while monitored by the hyperbaric medicine team. Six hours after the 
commencement of treatment with HBO, patients received either single (n=8) or double (n=7) units of 
UCB. They were monitored for adverse events and severe adverse events as a result of the HBO, in 
addition to standard-of-care post-transplant supportive treatment and monitoring. A schematic of the 
HBO treatment can be seen in supplemental figure S1. EPO levels were measured in these patients both 
before, and 8 hours after HBO treatment.  
Chart Review 
 The fifteen patients of the HBO-cohort had their charts reviewed by research staff to collect the 
following data: demographic data including age, gender, and race/ethnicity of the subjects. In addition, 
transplant-related data include: date of transplant, preparative regimen (reduced intensity or 
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myeloablative), number of cord units (single or double), degree of HLA matching of each unit, donor 
chimerism on day +30, +60, +100, +180, and +365 post-transplant, date and cause of death, and date of 
relapse. Data was also collected on their post-transplant transfusion and growth factor requirements. 
The numbers of supportive platelet/packed red blood cell (PRBC) units required were tabulated, along 
with the time to transfusion independence (TTI) for both categories of blood products. The consecutive 
days of granulocyte-colony stimulating factor (G-CSF), also known as neupogen, support was also noted. 
These variables were obtained for the second group needed for comparison: UCB-recipients at the same 
institution, which underwent transplant between the years 2008 and 2014. (n=45) 
Statistical Analysis 
 For these comparisons, Kaplan-Meier survival curves were used, Differences between HBO 
versus controls were determined using the log-rank test.  Some of the observations were right-
censored.  For subjects with a value of 0, a small quantity (0.1) was imputed to facilitate including these 
subjects in the analyses. For determining significance, data were compared between the HBO and 





HBO Tolerance and Exclusions 
 There were no adverse events or severe adverse events that were determined to be a result of 
the HBO during the follow-up period of 100 days for this study. Patients who experienced either relapse 
of disease or who expired during the first 100 days were excluded from the quantification of PRBC and 
platelet unit analyses and TTI calculations. They were, however, evaluated to determine if transfusion 
independence had been achieved prior to these events, and included if this was demonstrated in their 
records.  
 The means of the summative data for this study can be found in Table 3.1. Table 3.2 reports the 
median values for each of the transfusion and growth factor parameters measured.  
 
Table 3.1: Comparison of means between HBO and standard historic patients according to preparative regimen and number 






Mean Days G-CSF 
Support 
Mean TTI - 
PRBC 
Mean TTI - 
Platelets 
HBO-total (n=15) 




Standard-Total (n=44) 9.29 17.14 35.02 56.09 54.8 
HBO-Ablative (n=6) 5.43 (p=0.23) 7.86 (p=0.16) 26.63 (p=0.07) 24 (p=0.53) 25.5 (p=0.45) 
Standard-Ablative 
(n=23) 
11.93 22.29 35.65 66.13 67.78 
HBO-RIC (n=9) 




Standard-RIC (n=21) 7.52 13.71 34.33 45.09 40.57 
HBO-Single UCB (n=8) 5.43 (p=0.19) 7.87 (p=0.26) 26.63 (p=0.06) 24 (p=0.06) 25.5 (p=0.06) 
Standard-Single UCB 
(n=4) 
10.25 24 36.2 74.4 70.2 
HBO-Double UCB 
(n=7) 
12.57 (p=0.87) 24.86 (p=0.95) 33.57 (p=0.70) 43 (p=0.74) 42.71 (p=0.95) 
Standard-Double UCB 
(n=40) 







Table 3.2 Median values for HBO and standard historic patients according to preparative regimen and number of UCB units 






Median Days G-CSF 
Support 
Median TTI - 
PRBC 
Median TTI - 
Platelets 
HBO-total (n=14) 9 9 29.5 34 30.5 
Standard-Total (n=44) 7 16 32 40.5 35.5 
HBO-Ablative (n=6) 12 19.5 29.5 51.5 46 
Standard-Ablative 
(n=23) 11.5 19.5 34 41 41 
HBO-RIC (n=8) 4 6 28 23.5 25.5 
Standard-RIC (n=21) 6 11 31 38 33 
HBO-Single UCB (n=7) 4.5 6 27.5 22 25 
Standard-Single UCB 
(n=4) 11 22 37 37 49 
HBO-Double UCB (n=7) 11 19 33 46 44 
Standard-Double UCB 
(n=32) 7 13 31 40 35 
 
Supportive Blood Product/Growth Factor Summations 
 As seen in Figure 3.1, the mean values of PRBC and platelet units were consistently lower from a 
numeric standpoint for all comparative categories for the HBO-cohort. The exception was found in the 
number of platelet units required for HBO patients in the setting of double cord-blood recipients. 
Differences in means most likely did not reach significance due to the small sample size of the HBO-
cohort. Since HSPC-transplant recipients have specialized transfusion requirements after transplantation 
to deter alloimmunization to HLA-differences, minimizing the number of transfusions is advantageous 
from a clinical perspective.122 Therefore, HBO-therapy would be an excellent choice for patients who are 








Figure 3.1: Comparison of means for supportive blood product usage in HBO-patients versus controls during the first 100 
days post-transplant 
Values represented as means +/- standard error. (A) HBO-therapy provides an overall decrease in blood product usage 
regardless of conditioning regimen or units transplanted.  (B) Side-by-side comparison of blood products required as a function 
of the number of UCB-units infused for transplant for the HBO-cohort and control patients. (C) Side-by-side comparison of 
blood products required as a function of the pre-transplant conditioning regimen for the HBO-cohort and control patients. 
 
Growth Factor Requirements 
 Standard of care for patients experiencing neutropenia secondary to their pre-transplant 
conditioning regimens is the administration of an exogenous growth factor, G-CSF, until neutrophil 
counts have stabilized above >1000 neutrophils/L.123 Decreasing the neutropenic time for these 
patients post-transplant reduces their risk for developing potentially fatal infections. Therefore, by 
tabulating the required days of G-CSF support, a comparison between the control UCB-patients and 
HBO-treated patients may be created. This measure gives information for the performance of the graft. 
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A graphic representation of the duration of G-CSF treatment for all patients may be found in Figure 3.2. 
In each stratification of the patient data, the mean values for days of G-CSF treatment are lower for 
patients in the HBO-cohort, though these results did not reach significance. With the exception of those 
patients receiving single-cord UCB-transplants (where n=4 of the control data, Figure 2D), the range of 





Figure 3.2: Comparative quantification of G-CSF support required post-UCB transplant 
Each point represents an individual patient’s requisite duration of treatment (days). Means are represented by bars – the values 
of which are tabulated for comparison in table 1. (A) Days of G-CSF support for all UCB-recipients, comparing HBO-treated 
patients with controls. (B) Comparison of control and HBO-patients who underwent reduced intensity conditioning. (C) 
Duration of G-CSF treatment for HBO-patients versus control, who underwent myeloablative conditioning. (D) Days of G-CSF 






Time to Transfusion Independence 
 Most notably, patients in the HBO-cohort experienced significantly less time to transfusion 
independence (TTI) for both PRBC and platelet support than the standard UCB-recipients.  TTI for 
platelets was defined as the day of the last, post-transplant platelet transfusion, with no platelet 
transfusions in the following seven days. Red blood cell TTI was defined as the day of the last PRBC 
transfusion with no transfusion in the following thirty days. For visualization purposes, the ratio of 
patients that were independent by day, compared to the total cohort, can be found in Figure 3.3. In fact, 
by days 66 and 74 post-transplant, 100% of HBO-patients were PRBC and platelet independent, 
respectively. This compares to incomplete platelet (88.63%) and PRBC (86.36%) independence in their 
standard-UCB-transplant counterparts at day 100. For reasons listed above, decreasing the TTI for 






Figure 3.3: Time to transfusion independence for PRBC and platelets in the HBO-cohort, compared to standard UCB-
transplant recipients 
(A) Depicts the ratio of patients who have achieved PRBC-independence to the total cohort, by day. 100% of HBO patients were 
independent by day 66 post-transplant compared to incomplete (86.37%) independence by day 100 for standard-UCB 
recipients. (B) Graphic representation of the ratio of platelet independence for each patient cohort, by day. 100% of HBO 
patients were independent by day 74, where the standard-UCB recipient patients had incomplete cohort independence by day 
100 (88.63%).  
 
Erythropoietin and Mechanism 
 In our previous studies, the reduction in EPO in vitro demonstrated an increase in SDF-1 
mediated chemotaxis of UCB-derived HSPCs. Therefore, EPO levels in patient serum were measured 
before HBO, and 8 hours after HBO, when the UCB-CD34+ cells would be actively homing to the bone 
marrow. Levels of EPO were reduced in all patients after HBO. The previously-described trend of MAC 
producing higher levels of endogenous EPO than RIC patients was observed, and can be found in Figure 
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3.4. However, there was no correlation between the serum levels of EPO, the units of PRBC/platelets 




Figure 3.4: Comparative mean erythropoietin levels of patients in the HBO-cohort 



































 The use of hyperbaric oxygen for aiding in HSPC transplant is a novel approach to improve bone-
marrow (BM) homing of HSPC, and is of particular importance in the context of UCB transplants, where 
reduced CD34+ numbers are available in the graft. HBO is a generally safe and well-tolerated therapy, 
with the most common risks being sinus and middle-ear barotrauma (2% of cases). 124 The only absolute 
contraindication to date for HBO is untreated pneumothorax. HBO-chambers are widely available in 
large academic medical centers globally, due to their use for emergent treatments in the instances of 
carbon monoxide toxicity and decompression sickness.125  
 In the case of HSPC transplant, it is noteworthy that these patients have a comparatively heavy 
pharmaceutical load at the time of transplant. However, concern that there might be a 
pharmacodynamic exacerbation of adverse drug events is mostly unfounded. In fact, no synergistic 
effect of pulmonary toxicity for bleomycin patients undergoing HBO therapy has been documented.126 
HBO has also mitigated the cardiotoxic effects of doxorubicin in a rat model of concurrent HBO and drug 
treatment. 127 While there may be some rare free-radical trauma associated with oxygen toxicity,128 a 
single treatment of HBO that improves engraftment and minimizes the necessary supportive post-
transplant care should be investigated. 
 The results for this study, at present – did not reach significance. This is most likely due to the 
small sample size of the HBO-cohort. The addition of more patients to this study will provide interesting 
insights for HBO therapy’s effect on the post-transplant supportive transfusion requirements in these 
UCB-recipients. Most noteworthy in this study, however, was the fact that there was no correlation with 
the level of EPO in patient serum with any of the following metrics for improved clinical outcomes: the 
quantitative numeration of blood products received, the TTI, or the days of G-CSF support.  
 Previously, our group reported an inverse correlation between circulating levels of EPO and BM-
homing of UCB-CD34+ cells in mice. HBO increased the amount of UCB-CD34+ cells present in the bone-
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marrow after transplant – an effect that was mitigated by a post-HBO “rescue” dose of EPO.119 It stands 
to reason, then, that the EPO levels in these human subjects should correlate to better engraftment. The 
serum levels of EPO were indeed transiently reduced immediately after HBO therapy; markers of 
engraftment such as neutrophil, platelet, and RBC recovery were improved compared to the historic 
controls (but did not reach significance). However, these did not correlate directly with EPO levels, or 
even a metered reduction in serum EPO. Therefore, while EPO has shown to play a mechanism in 
homing, it is possible that there are other physiological factors on a multi-organ-system-level that 
respond to HBO and aid in HSPC engraftment.  
 It has been demonstrated that there is a necessary polarized domain on CD34+ cells to interact 
with the BM-microenvironment.129 Specifically, CD82 is needed for osteoblastic adhesion, but CXCR4, 
VLA-4, and CD44 are also important on the CD34+ HSPC for insertion into the BM-hematopoietic niche. 
Future studies for the mechanism of HBO-induced engraftment could target its specific effects on the 
regulation of these specific co-markers for this homing-capable population of CD34+ HSPCs.   
 It is important to note that since HBO is a global therapy for in vivo models, there are other 
critical interactions, both in the vasculature and within the BM-microenvironment, which could shape 
the progress of HSPC engraftment. Within the marrow itself, HBO has shown to significantly treat 
transient BM-edema in the femoral head compared to controls.130 In this same context of wound 
healing, HBO has attenuated inflammation and apoptosis in areas of ischemia, and has been shown to 
decrease neutrophil extravasation from blood vessels.131 The attenuation of inflammation could feasibly 
increase the available CD34+ HSPC available for engraftment: particularly in the case of UCB cells, where 
the required degree of HLA-matching is not as stringent.109  
 HBO can also affect another critical component of the BM-microenvironment: the mesenchymal 
stem cell (MSC). MSCs have been documented to provide an array of supportive factors within the 
hematopoietic niche.61, 132 The effects of HBO on MSCs have been studied in the context of ischemic 
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injury repair, for which both HBO and MSC-therapy have been individually employed.133 Via Wnt-
signaling, HBO also increases the differentiation of MSCs into an osteogenic lineage.134 Therefore, it is 
entirely possible that this crucial interaction between MSCs and HSPCs in the BM-microenvironment is 
improving homing and engraftment in the HBO model. Further in vitro studies of the 
immunomodulatory capacities of MSCs when subjected to HBO are currently underway to determine if 








Figure 3.S3.5: Schematic of HBO Treatment 
 
 


































































































Chapter 4: A Brief Examination of Hyperbaric Oxygen on Mesenchymal Stem 







 The clinical use of hyperbaric oxygen (HBO) has been proven to improve clinical outcomes in 
HSPC-transplant. The correlation of these outcomes by post-transplant transfusion requirements to 
levels of erythropoietin did not replicate previous findings in animal data. Therefore, the manipulation 
of the immunomodulatory factors produced by mesenchymal stem cells (MSCs), a component in the 
hematopoietic niche, was examined. Differences between the functionality of CD105+/- MSCs have also 
been documented. Because of the relationship between CD105 expression and tissue oxygen tension, 
this study sought to examine how HBO affects the expression of CD105 in various MSC-populations and 
any correlative changes of selected immunomodulatory factors produced by these MSCs.  
 MSCs were procured from mouse bone marrow, sorted for their CD105 expression, and exposed 
to HBO. Expression analyses were performed before HBO-treatment, immediately following treatment, 
and 12 and 24 hours after treatment. Transcriptional changes in CCL2, CD105, IL-6, iNOS, PTGES, and 
TGFwere assessed by qPCR after HBO treatment and normalized to controls. MSCs were subsequently 
procured from a human Wharton’s Jelly source and subjected to identical treatments and qPCR 
analyses. These WJ-MSCs also had their CD105 surface expression tracked by flow cytometry at the 
aforementioned time-points.  
 IL-6 was consistently upregulated immediately following HBO treatment for CD105+/- BM-MSCs 
and WJ-MSCs. Potential subsequent effects of this upregulation showed increased expression of iNOS, 
PTGES, and TGF at the 24 hour time-point. These effects were exaggerated in the CD105- population 
compared to CD105+ BM-MSCs. This increase in expression was not consistent in the WJ-MSCs, which 
demonstrated a statistically significant downregulation in PTGES and TGF at the 24 hour time-point. 
The expression of CD105 was consistently upregulated immediately following HBO treatment, followed 
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by a downregulation to its lowest expression level 12 hours after the termination of treatment. This held 
for all MSCs regardless of their source or prior CD105 expression, and was confirmed by flow cytometry. 
 Inconsistencies between the CD105+/- BM-MSCs and the WJ-MSCs may stem from the paracrine 
effects of the secreted immunomodulatory factors within the cell cultures, or from basic physiologic 
differences between the cell-source for these MSC populations. However, the consistent 
downregulation of CD105 may present a mechanism by which MSCs enhance homing of HPSCs to bone 








 Hyperbaric Oxygen (HBO) presently has a therapeutic role for the treatment of a variety of 
conditions, including but not limited to: carbon monoxide poisoning, air embolism, traumatic ischemia, 
problematic wound healing and other conditions linked to poor perfusion.128 Most notably, HBO has 
recently been used to improve the efficacy of bone marrow engraftment in the context of 
hematopoietic stem/progenitor cell (HSPC) transplant in both animal models and human trials.119 In this 
study, both human and animal subjects were subjected to HBO-therapy prior to transplantation, and 
demonstrated significant improvement of graft performance over time. In the animal models, HBO-
therapy was shown to reduce the production of erythropoietin (EPO), which subsequently and 
causatively led to improved homing of the graft.  
 However, the human studies indicated that neither the level of EPO nor HBO-induced EPO 
reduction correlated with need for supportive transfusion care post-transplant, which had been 
assessed as a marker of graft performance. Moreover, the patients did experience less need for 
transfusion support after transplant using HBO-conditioning. Therefore, perhaps there are other factors 
which led to the improved homing and engraftment seen in these patients. Since the entire host was 
treated with HBO prior to transplant, it is not unreasonable to believe that the HBO-therapy could have 
caused changes within the bone marrow niche itself that helped improve engraftment in these patients. 
 There is a cell type that exists within the bone marrow (BM) niche that plays a supportive role in 
maintaining the HSPC microenvironment: the mesenchymal stem cell (MSC). MSCs have been 
documented to provide supportive factors within the hematopoietic niche.61, 132 Additionally, the effects 
of HBO on MSCs have been studied in the context of ischemic injury repair, for which both HBO and 
MSC-therapy have been individually employed.133 Therefore, it is possible that this crucial interaction 




 However, MSCs are varied in source and have inconsistencies within their definitive marker 
profile.1 The disparity in these marker profiles has led to the investigation of physiological differences 
between MSCs and their capacities for self-renewal, differentiation, and immunomodulation.2, 3 One 
such marker that has been studied is endoglin (CD105). CD105 is a multifunctional protein with the 
capacity to modulate members of the transforming growth-factor  (TGF superfamily,18 and its 
presence/absence has led inquiries into its capacity to modify this signaling as it relates to the 
endogenous and therapeutic roles of MSCs.2, 3 It is noteworthy that CD105 also increases as a response 
to hypoxia.135 Therefore, changes in the expression of endoglin on MSCs is likely to change as a result of 
exposure to HBO - the capacity of that MSC to perform immunomodulatory functions may indeed be 
altered as a result. 
 Previously, we have demonstrated that differences in CD105 expression on MSCs play a role in 
the differentiation of T-cells in vitro. The mechanism by which this occurs is still currently under study. 
However, MSCs have been documented to produce C-C Motif Chemokine Ligand 2 (CCL2)136, inducible 
Nitric Oxide Synthase (iNOS)137 Interleukin-6 (IL-6)138, Prostaglandin E2 (PGE2)139, and members of the 
TGFsuperfamily. 139 There exists a possibility that HBO-therapy can modify the immunomodulatory 
capacity of MSCs by changing the levels of these secreted factors during the crucial homing-window of 
HSPC transplant. Therefore, by examining the effects of HBO on these factors, and any resultant 
correlations with the expression of CD105, insight into how HBO changes the BM-microenvironment will 





Murine BM-MSC Isolation 
 The method for murine BM-MSC isolation can be found in Chapter 2: Methods, under MSC 
Isolation.  
Flow Cytometry Based Sorting for CD105+/CD105- BM-MSC populations 
 The method for sorting of these BM-MSC populations can be found in Chapter 2: Methods. The 
BM-MSCs in this study were subjected to experimental variables between passages 7-10. 
Human Wharton’s Jelly-MSC Isolation 
 Wharton’s Jelly MSCs (WJ-MSCs) are isolated from human umbilical cord segments following an 
IRB approved-informed consent process.  Potential donors were expectant mothers between 38-42 
weeks in gestation and have negative viral serology for Human Immunodeficiency Virus Type 1 & 2, 
Hepatitis A, B and C, HTLV 1 & 2, Treponema pallidum, Chlamydia trachomatis and Neisseria gonorrhea.  
Donors who meet these criteria were consented to donate the umbilical cord from their parturition. 
Following birth, donated umbilical cords are placed in cool 1x-phosphate buffered saline (1xPBS) 
containing 100 IU/mL of penicillin and 100 µg/mL of streptomycin (Cellgro) and stored at 4°C until 
transfer to the laboratory. 
 To process the donated cord, the tissue is thoroughly washed with the same antibiotic/PBS 
mixture used for transport, in order to remove traces of blood and minimize potential bacterial 
contamination.  The cord is cut into small segments and washed in sterile PBS, supplemented with a 
greater antibiotic concentration of 200 IU/mL of penicillin and 200 µg/mL of streptomycin (Cellgro).  The 
cord sections are then opened such that three blood vessels can be removed.  The clean cord is then 
minced with sterile scissors into 2- to 3-mm fragments and incubated in xeno-free, serum-free media 
86 
 
(Miltenyi), to permit cellular migration and extravasation from the tissue and adhere to the tissue 
culture dish.  
 WJ-MSC migration and adherence to the tissue culture plates occurs over a 2-3 week period.  
Following the migration of WJ-MSCs out of the umbilical cord, cord tissue is removed and the cells are 
allowed to expand to approximately 80-90% confluency, at which time they are harvested using TrypLE 
(ThermoFisher Scientific) and are ready for expansion. The cultures are expanded to Passage 5, 
increasing the number of available WJ-MSCs approximately 1300-fold.  Cells recovered from Passage 5 
are counted and stored in liquid nitrogen until use for the hyperbaric oxygen assays.  
Hyperbaric Oxygen Treatment of MSC Groups 
 Both BM-MSCs and WJ-MSCs were cultured for 2-3 passages following recovery from the frozen 
state. The cells were then plated into T-75 tissue culture flasks. Once the confluence of these passaged 
cells reached 70-80%, one set of the MSCs were harvested for a pre-treatment comparative control. The 
remaining MSCs were treated with 100% O2 for 2 hours at 2.5 ATM. To control for the influence of 
temperature change and hypocarbia, control plates were incubated in room air adjacent to the HBO-
chamber for the same duration of time. Cells were harvested for mRNA and protein immediately 
following treatment (Time 0) and at 12 and 24 hours following the termination of the HBO treatment.  
Flow Cytometric Analysis of CD105 Expression 
 WJ-MSCs were harvested before HBO treatment and at the experimental time points listed 
above. 5L of FITC-conjugated anti-CD105 was added to 1x106 cells for each of the control and 
treatment groups for the identification of CD105+ cells. Using BD FACS Diva software, MSCs were gated 
for the appropriate size and the doublet-fraction was excluded. An example of the creation of these 
gates can be found in Figure 4.2A. Using unstained controls for each sample, a histogram gate was 
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created for determining the percentage of CD105+ cells in the sample. These results were tabulated and 
compared for significance using a student’s t-test.  
Isolation and Quantification of mRNA  
 The method for RNA isolation and cDNA conversion can be found in Chapter 2: Methods. Primer 
sequences for the studies in this chapter can be found in supplemental tables 4.S1 and 4.S2 for mouse 
and human specific primers, respectively.  
 The resultant CT values from each of the reactions were normalized using the CT values of 
hypoxanthine phosphoribosyltransferase (HPRT) as an internal control for the murine cells and 
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) for the human cells, creating a CT value for each 
sample. The CT was calculated by subtracting the factor-specific CT from time-correlated non-HBO 
treated controls. The fold change was calculated by the following equation: 
𝐹𝑜𝑙𝑑 𝐶ℎ𝑎𝑛𝑔𝑒 =  2−(∆∆𝐶𝑇) 





Transcriptional Changes for HBO Treated CD105+/- BM-MSCs 
 To determine the potential effects of HBO-treatment on BM-MSCs, the sorted CD105+/- 
experimental groups underwent transcriptional expression analysis via qPCR for the factors: CCL2, iNOS, 
IL-6, prostaglandin E2 synthase (PTGES; for the production of PGE2), TGF1, and CD105. The data were 
normalized to an internal control (HPRT) and fold change was calculated by use of control samples that 
were not treated with HBO. The changes in these immunomodulatory factors can be seen in Figure 4.1. 
Figure 4.1A depicts changes from the CD105+ population of cells. There were some differences between 
the replicates. The first replicate shows increasing fold changes in the 12 and 24 hour time points for 
iNOS, PTGES, and TGF. The second replicate shows these are upregulated to their highest degree 
immediately following HBO-treatment (Time 0). However, both consistently show that IL-6 is most 
prominently upregulated immediately following HBO-treatment. The expression of CD105 for both 
replicates, however, demonstrates a transient upregulation immediately following HBO-treatment, 
followed by a downregulation at 12 hours. There were minor and inconsistent changes for CCL2.  
 The changes in response to HBO-treatment demonstrated by the CD105- MSCs were dramatic 
compared to CD105+ correlates, but there were consistencies in the pattern of CD105 expression over 
time. While these cells were CD105- by surface marker expression at the beginning of this experiment 
(data not shown) the transcriptional levels of CD105 transiently increased immediately post-HBO and 
then decreased to its lowest level at 12 hours, as seen in Figure 4.1B. There was also consistency 
regardless of CD105 expression for the immediate upregulation of IL-6 post-HBO. This was followed by a 
downregulation in one of the CD105- replicates. The other replicate did not follow this pattern, showing 
a marked 17.64-fold upregulation 12 hours after treatment.  
 However, there were differences in the patterns of expression for iNOS. Figure 4.1C shows the 
24 hour transcriptional data for all factors in the CD105- HBO-treated BM-MSCs, such that the intensity 
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of the fold-changes did not diminish the other data by scale, seen in Figure 4.1B. While the CD105+ BM-
MSCs did show iNOS upregulation in one replicate at 24 hours, the CD105- cells showed a 38.15-fold and 
a 8.23-fold upregulation in their replicates, which dominates the CD105+ cells’ upregulation at 2.45-fold. 
Similarly, PTGES and TGF were dramatically upregulated at the 24 hour time point in both replicates 
for the CD105- populations. For all time points, CCL2 did not have drastic or consistent changes, much 





Figure 4.1: Expression data for CD105+/- BM-MSCs treated with HBO 
Represented is the qPCR analysis for immunomodulatory factors from HBO-treated BM-MSCs for two separate replicates of the 
HBO-treatment. (A) CD105
+
 BM-MSCs responded to treatment with HBO with factor changes that were consistently 
upregulated between replicates for PTGES and TGF at the 24 hour time-point. PTGES was upregulated 5.47 and 3.91-fold, 
where TGF changed with a 4.71 and 2.19-fold increase in expression. Both trials also demonstrate a transient increase in 
CD105 expression immediately post-treatment (1.24 and 5.60-fold at Time 0) followed by a decrease 12 hours later (1.12 and 
0.48-fold). These data also demonstrate a consistent increase in IL-6 expression at Time 0 (2.44 and 9.71-fold), which tapers off 
at later time-points. (B) CD105
-
 data are represented here without the 24 hour time-point such that they are not diminished by 
the necessary increases in scale. Compared with the CD105
+
 cells, there were similar patterns for IL-6 production with a 
transient increase in expression immediately post-treatment, (2.95 and 3.91-fold) but this pattern does not persist for the 
replicate depicted on the right, where IL-6 is upregulated by 17.64-fold 12 hours after HBO treatment. The pattern of a 
transient increase in CD105 expression immediately post-HBO, followed by a downregulation at the 12 hour time point, is 
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consistent with the CD105
+
 counterparts in the replicate seen on the left (1.46-fold for Time 0 and 0.55-fold for Time 12). The 
figure on the right also demonstrates this decrease at 12 hours (0.48-fold), but not the transient increase at Time 0 compared 
to the pre-treatment sample (1.32 and 2.42-fold, respectively). (C) The 24 hour CD105
-
 HBO treatment expression values are 
depicted separately such that the scale does not interfere with visualization of the fold-changes of other time points. Similar to 
the CD105
+
 cells, the expression of IL-6 normalized for both replicates by 24 hours despite the upregulation seen in earlier time-
points (1.02 and 0.08-fold at 24 hours). CD105-expression also increased (3.4-fold) and normalized (0.96-fold) for the replicates 
depicted on the left and right. This is consistent with the pattern seen between time-points for the CD105
+
 BM-MSCs. TGF, 
PTGES, and iNOS all had the most dramatic upregulation in expression at the 24 hour time-point. iNOS increased 38.15-fold for 
the replicate on the left and 8.23-fold for the right. This compares with mild upregulation for the CD105
+
 counterparts at 2.44 
and 1.66-fold. PTGES was upregulated 22.33-fold and 6.35-fold in these two CD105
-
 replicates. TGF expression increased by 
38.56 and 4.21-fold for the two trials. Both PTGES and TGF show upregulation in CD105
+
 at the 24 hour time-points, but not to 
the degree that was seen in the CD105
-
 cells.  
 
CD105 Expression of WJ-MSCs with HBO Treatment 
 Since the hyperbaric oxygen clinical study was performed on human subjects, human WJ-MSCs 
were employed in a similar expression analysis. Using flow cytometry at the following time points: 
established pretreatment, immediate post-treatment, 12 hours, and 24 hours post treatment, the 
functional surface expression of CD105 was ascertained from these cell populations. These were 
compared to non-HBO-treated controls in Figure 4.2. Using gating parameters to isolate the size-
appropriate WJ-MSC population (Figure 4.2A), the percent of cells expressing CD105 was assessed. 
Consistent with the BM-MSC transcription data, WJ-MSCs experience a statistically significant, transient 
increase in surface CD105 expression immediately following HBO-treatment compared to controls. As 
seen in Figure 4.2B, the expression of CD105 then diminishes significantly between Time 0 and Time 12, 
before it normalizes with controls at 24 hours. Differences between the Time 0 treatment group and the 








Figure 4.2: Expression of CD105 on WJ-MSCs during the course of HBO treatment assessed by flow cytometry 
Values represented as means±SEM. (A) Construction of gates for size by SSC-A vs. FSC-A (left), and exclusion of doublets by FSC-
H and FSC-A (second from left) isolated the WJ-MSCs for examination of CD105 expression. The top histogram panel 
demonstrates the creation of a gate (P2) for the demarcation of CD105 expression from an identical sample that was unstained 
with FITC-conjugated anti-CD105. The bottom histogram panel depicts the same sample stained with antibody. Highlighted in 
red on the statistics view (right) is the percentage value of the parent population for CD105
+
 cells. This was tabulated for each 
sample. (B) Graphic representation of CD105 expression at each time point, compared with controls. The pre-treatment group 
(far left) is indicated by the green color. Statistically significant changes in percent CD105 expression occurred at Time 0 
between HBO-treated and control samples at 16.675%±0.46 and 9.65%±0.53, respectively (p<0.0005). The decrease of the 
CD105 also reached statistical significance between Time 0 and both 12 and 24-hours post-treatment with expression of 
10.17%±2.18 at Time 12 (p<0.05) and 8.73%±0.87 for Time 24 (p<0.0005). The pre-treatment group expressed CD105 at 
14%±1.22 which was significantly greater than the HBO-treated group (8.725%±0.87) at the final time-point (p<0.05), though 
the treatment group had normalized to controls by this time post-treatment (8.70%±1.77 for controls). (n=4) 
 
Transcriptional Changes for HBO-Treated WJ-MSCs 
 Compared with the BM-MSC groups, the fold-changes seen in the WJ-MSCs were both smaller in 
scale and demonstrated different patterns of expression by time-point for several of the observed 
factors. However, among the factors where patterns were consistent between BM-MSCs and WJ-MSCs 
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was IL-6, where there was an initial upregulation at the termination of HBO-treatment that 
subsequently tapers off over time. CCL2 also did not demonstrate consistent or drastic changes in 
upregulation, as with the CD105+/- BM-MSCs. Interestingly, PTGES and TGF – which demonstrated 
prominent expression in both BM-MSC groups at 24 hours, showed a statistically significant 
downregulation over time in the WJ-MSCs.  
 The expression of CD105, however, correlated with the BM-MSC transcriptional changes and 
with the data acquired by use of flow for functional CD105 expression. The transient increase seen in 
the aforementioned groups was not seen at the Time 0 collection, however, the lowest level of 
expression was consistently found 12 hours after HBO-treatment. While these did not reach statistical 









Figure 4.3: Transcriptional changes for HBO-treated WJ-MSCs over 24 hours  
Values represented as means±SEM. Treatment of the WJ-MSCs revealed differences in patterns than those from the BM-MSCs 
with HBO treatment. For the factor PTGES, samples between which differences reached statistical significance were Time 0 
(1.12-fold±0.21) and Time 24 (0.41-fold±0.03) (p<0.05). The only factor which demonstrated similar significance was for TGF 
between the pretreatment group that had very little change in expression (1.01-fold±0.08) and the 24 hour post-treatment 
group with 0.60-fold ±0.11 change. (p<0.05) Similar patterns were seen for CD105 expression in both the active expression by 
flow (Figure 4.2B) and the HBO-treated BM-MSC experimental groups. The 12-hour time point for CD105 demonstrates the 







 This study provides interesting data comparing the functionality of MSCs from different sources 
and with varying expression of CD105. Some of the limitations for this study were created by insufficient 
CD105+ BM-MSC numbers, halting the transcriptional analysis for BM-MSCs at only two replicates. 
However, the patterns demonstrated by CD105+/- BM-MSCs in those two replicates may have some basis 
in the physiology of these immunomodulatory factors. Since these experiments are concerned with the 
expression of secreted factors, it is not unreasonable to suspect that these factors have paracrine effects 
on their neighboring cells, causing changes in their transcription profile. Therefore, the initial 
transcription changes could have a cascading effect for the subsequent immunomodulatory factors. IL-6 
has been documented to induce iNOS, 140 which is consistent across CD105+/- BM-MSC groups. IL-6 is 
consistently upregulated in response to HBO, either immediately following or 12 hours after treatment, 
and iNOS follows suit 24 hours later – most dramatically in the CD105- groups.  
 Interestingly, TGF1 has been shown to attenuate iNOS expression in the context of in vitro 
hypoxia-reperfusion models of cardiomyocyte injury. 141 The upregulation of iNOS that may be caused by 
IL-6 could, in fact, be evoking this drastic TGF-response in the BM-MSCs 24 hours after HBO exposure. 
PGE2, the product of PTGES, also is an enhancing element of TGF1 which could be a response to iNOS 
upregulation. 142 PGE2 could also be causative for the iNOS upregulation, as it has been demonstrated to 
mediate its presence in the context of breast cancer studies.143 Therefore, the interplay between these 
factors could be causing the drastic differences seen in the BM-MSC context. These effects could 
potentially be exaggerated in the CD105- group, as the lack of endoglin could prohibit the attenuating of 
TGF responses via Smad signaling.14 
 These transcriptional changes were not present in the WJ-MSC treated with HBO. In fact, both 
TGF and PTGES demonstrated opposite trends of downregulation at 24 hours. It is noteworthy, 
however, that there have been studies dedicated to documenting the functional differences between 
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WJ-MSCs and BM-MSCs in the context of enhancing HSPC transplantation.144 In this study, they 
demonstrate that WJ-MSCs have a more suppressive effect than the BM-MSC counterparts on T-cell 
proliferation. Additionally, co-culture of CD34+ HSPCs with BM-MSCs yield more erythroid colonies than 
WJ-MSCs, which yield more myeloid/granuloid colonies. Therefore, there is a physiologic and functional 
difference between these cell groups. This is visible even in the baseline, pre-treatment expression data 
for the WJ-MSCs compared to the BM-MSC populations. In light of these differences, making direct 
comparisons of the WJ-MSCs and BM-MSCs may not be informative for determining the differences in 
immunomodulatory factor change with HBO treatment. Additionally, limitations in primer design for 
human iNOS prohibited the examination of this integral piece that could connect the 
immunomodulatory factors examined.  
 This study was novel in its examination of the responsive expression of endoglin to hyperoxia. As 
stated previously, CD105 is a well-documented hypoxia response element.135 Here, this study 
demonstrates that there is a consistent change in the expression of CD105 on MSCs as a result of HBO. 
Both CD105+/- BM-MSC and WJ-MSCs demonstrate a consistent, transient increase in CD105 expression 
immediately following treatment, followed by the most significant decrease at 12 hours. This was 
validated both by flow cytometry and by qPCR. The timeline of CD105 downregulation might be 
important in the context of using HBO for improving engraftment in HSPC-transplant studies. Our 
previous clinical study made use of cord-blood derived HSPCs infused 6 hours after the initiation of HBO. 
Since BM-homing occurs within the first 18 hours after infusion into these irradiated hosts,129 the timing 
of CD105 downregulation by MSCs in the hematopoietic bone marrow niche may play a role in the 
ability of HSPC to home and engraft in these spaces.  
 To confirm the hypothesized roles of HBO-changes in both MSC-immunomodulation and 
modification of MSCs in the bone marrow niche, further studies are currently being conducted to 
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strengthen existing data and explore how these transcriptional changes relate to the expression of their 







Table 4.S4.1: qPCR primer sequences for mouse-specific immunosuppressive factors secreted by MSCs 
Primer Name Primer Sequence (5'-3') 
Mouse HPRT Forward GGCCAGACTTTGTTGGATTTG  
Mouse HPRT Reverse CGCTCATCTTAGGCTTTGTATTTG  
Mouse iNOS Forward CAGGGAGAACAGTACATGAACAC 
Mouse iNOS Reverse TTGGATACACTGCTACAGGGA 
Mouse CCL2 Forward TAAAAACCTGGATCGGAACCAAA 
Mouse CCL2 Reverse GCATTAGCTTCAGATTTACGGGT 
Mouse IL-6 Forward CTGCAAGAGACTTCCATCCAG  
Mouse IL-6 Reverse AGTGGTATAGACAGGTCTGTTGG 
Mouse TGF1 Forward CTTCAATACGTCAGACATTCGGG 
Mouse TGF1 Reverse GTAACGCCAGGAATTGTTGCTA 
Mouse PTGES Forward CACACTGCTGGTCATCAAGAT 
Mouse PTGES Reverse TCACTCCTGTAATACTGGAGGC 
Mouse CD105 Forward AGGGGTGAGGTGACGTTTAC 
Mouse CD105 Reverse GTGCCATTTTGCTTGGATGC 
 
Table 4.S4.2: Human-specific primer sequences for immunosuppressive factors secreted by MSCs 
Primer Name Primer Sequence (5'-3') 
Human HPRT Forward CCTGGCGTCGTGATTAGTGAT 
Human HPRT Reverse AGACGTTCAGTCCTGTCCATAA 
Human GAPDH Forward TCGACAGTCAGCCGCATCTT 
Human GAPDH Reverse GTCTGAGCGATGTGGCTCGG 
Human CCL2 Forward CAGCCAGATGCAATCAATGCC 
Human CCL2 Reverse TGGAATCCTGAACCCACTTCT 
Human IL-6 Forward ACTCACCTCTTCAGAACGAATTG 
Human IL-6 Reverse CCATCTTTGGAAGGTTCAGGTTG 
Human TGF1 Forward CTAATGGTGGAAACCCACAACG 
Human TGF1 Reverse TATCGCCAGGAATTGTTGCTG 
Human PTGES Forward TCCTAACCCTTTTGTCGCCTG 
Human PTGES Reverse CGCTTCCCAGAGGATCTGC 
Human CD105 Forward CGCCAACCACAACATGCAG 




Chapter 5: Conclusions and Future Directions 
 
Rationale for Study 
 The expression of endoglin (CD105) on mesenchymal stem cells (MSCs) has been a subject of 
study for several groups attempting to identify a more therapeutically beneficial MSC. Because endoglin 
modulates TGF signaling,18 it has presented itself as a target for several groups that seek to understand 
and improve the inherent MSC capacities for differentiation2, self-renewal,145 and immunomodulation.3 
As members of the TGF superfamily are involved in all these processes,145-147 the modulation of its 
effect by an endogenous factor like CD105 has provided an attractive candidate for study. 
 The work for this doctoral dissertation began with evidence from our previous studies that 
showed CD105- BM-MSCs provided more effective therapy than unfractionated controls for the 
maintenance of cardiac function when injected intramyocardially in an ischemia/reperfusion model of 
infarction. In vitro modeling also demonstrated that CD105- BM-MSCs had a greater propensity to 
differentiate into cardiomyocytes and form capillaries than unfractionated BM-MSCs. However, the 
work of Freyman et al in the European Heart Journal showed in a porcine model that the delivery of 
MSCs by multiple methods to an infarct only resulted in a maximum of 6% of retained cells.148 Because 
of this low retention, the mechanism by which the MSCs were reducing infarct-area fraction could not 
be solely the regeneration of new tissues. Because MSCs are known for their immunomodulatory 
capacity, it was hypothesized that the lack of CD105 expression on MSCs contributed to an immunologic 
milieu that reduced scarring following cardiac injury.  
Suppression and Differentiation by CD105+/- MSCs  
 By this rationale, the work presented in this dissertation attempted to clarify differences in 
immunomodulation between CD105+/- BM-MSCs.  Initially, the short-term goal was to replicate findings 
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that were reported in the 2013 publication from Anderson et al. The work in their paper showed that 
CD105- MSCs derived from adipose tissue had a greater suppressive effect on the proliferation of T-
cells.3 In Chapter 2 of this dissertation work, the establishment of a method that resulted in the 
proliferation of T-cells was accomplished. Factors under consideration to translate these into 
suppressive assays were: dosage of stimulating antibodies, dosage of MSCs to induce suppression, the 
benefits of a transwell culture system, and timeframe at which T-cell proliferation was to be assessed. 
Once these factors were determined, the examination of the suppressive effects of CD105+/- MSCs on 
CD4+ and CD8+ T-cells was undertaken. 
 However, as indicated by Figure 2.4, suppressive effects were mild and did not reach statistical 
significance between the CD105+/- MSC treatment groups for CD4+ syngeneic and allogeneic models. 
CD8+ cells, in fact, appeared to be stimulated in the allogeneic context. The lack of statistically significant 
differences between CD105+ and CD105- groups could be explained by the fact that these assays were 
performed specifically on CD4+ or CD8+ T-cells. The differentiation effects of MSCs in a mixed-splenocyte 
reaction have been shown to increase the proportion of regulatory T-cell phenotypes,106 and these cells 
could, in turn, decrease the overall proliferation of the mixed splenocytes via inhibitory cytokines.  
 The next logical step, therefore, was to compare the effects on differentiation for CD4+ T-cells by 
CD105+/- MSCs in both syngeneic and allogeneic models. The results in Figures 2.5 and 2.6 have 
demonstrated significant differences between syngeneic and allogeneic MSC-based differentiation 
cultures of CD4+ T-cells. Additionally, some of these effects can be correlated to the expression of CD105 
on the MSCs in co-culture. The expression data from these co-cultures suggest that the allogeneic 
setting induces the transcription of more Th2-associated factors. There were also consistently 
documented differences seen in the allogeneic CD105- co-culture groups for upregulation of these Th-2 
factors compared to their CD105+ counterparts. This prominent Th2 phenotype was confirmed by 
quantification of the secreted factors IL-4 and IL-10, which was significantly greater in the allogeneic 
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setting and for CD105- co-cultures. The quantification of IFN and IL-2 showing inconsistent results might 
be due to the timeline of the method for assaying these factors.  
Hyperbaric Oxygen and Hematopoietic Stem Cell Transplant 
 Throughout the course of these explorations into the immunomodulatory effects of CD105+/- 
MSCs, there was a concurrent novel clinical study for using hyperbaric oxygen (HBO) to improve the 
transplant outcomes of umbilical cord blood (UCB) recipients. The use of HBO was clinically significant in 
the reduction of supportive blood-product requirements by these transplant patients as seen in Figure 
3.1, which decreased their risk for transfusion-related adverse events. It also decreased the time to 
transfusion independence (TTI) for both packed red blood cells and platelets in these patients (Figure 
3.3). These data correlated to and confirmed the animal models that had been documented by this 
same group. 119  
 In the previous study, HBO-therapy was shown to reduce the production of erythropoietin (EPO) 
which subsequently and causatively led to improved homing of the graft in these animal models. 
However, the human studies indicated that neither the level of EPO nor HBO-induced EPO reduction 
correlated with a need for supportive transfusions in the post-transplant course (Figure 3.4)… Perhaps, 
then, there were other factors which led to the improved homing and engraftment seen in these 
patients. Thus, the hypothesis was developed that HBO-therapy could have caused changes within the 
bone marrow (BM) niche itself that helped improve the engraftment in these patients. MSCs have been 
shown to provide supportive factors within the hematopoietic niche.61, 132 The effects of HBO on MSCs 
have also been studied in the context of ischemic injury repair, for which both HBO and MSC-therapy 
have been individually employed.133 Therefore the hypothesis became that the interactions between 




Correlations between CD105 Expression of MSCs and Hyperbaric Oxygen Treatment 
 By examining the effects of HBO on secreted immunomodulatory factors, and potential 
resultant correlations with the expression of CD105, some insight was gained on this hypothesis. There 
were some consistent patterns in secreted-factor expression in the BM-MSC portion of the study 
between CD105+/- populations (Figure 4.1). However, limitations in these experiments only allowed the 
production of two replicates. Repetitions of this assay to strengthen these data are included in the 
future directions for the study. The studies on the human WJ-MSCs did not provide as dramatic or 
consistent data as the BM-MSC counterparts.  
 However, studies on the human WJ-MSCs were consistent in the most novel portion of these 
experiments, which was the examination of the HBO-responsive expression of endoglin. CD105 is a well-
documented hypoxia response element.135 This study demonstrated a consistent, reproducible change 
in the expression of CD105 on MSCs as a result of HBO. Both CD105+/- BM-MSC and WJ-MSCs 
demonstrate a transient increase in expression immediately following treatment, followed by the most 
significant decrease at 12 hours. This was validated in multiple assays, and can be seen in Figures 4.1, 
4.2, and 4.3. Since BM-homing occurs within the first 18 hours after infusion into these conditioned 
hosts,129 the timing of CD105 downregulation by MSCs in the hematopoietic BM- niche may play a role 
in the ability of HSPC to home and engraft in these spaces. 
Conclusions and Future Work 
 The picture of CD105 in the mesenchymal stem cell is incomplete, but there are several pieces 
that would give clarity to its physiologic and potentially therapeutic role. Primarily, a marker profile for 
which to define the mesenchymal stem cell is necessary. As previously stated, there are contradictory 
reports regarding the capacity of CD105 as a marker for a sub-set of MSCs with distinct capabilities, 
because there is such heterogeneity in the population. Additionally, the mechanism by which endoglin 
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functions to provide these differing MSC capacities should be explored as it has been in other cell types. 
As the field stands, the characterization of CD105+ versus CD105- cells is primarily characteristic instead 
of mechanistic. Discussed here were several papers and our own evidence, commenting on 
differentiation and functional capacities of these two different cell types, but there was very little 
decisive, conclusive evidence of how endoglin functions in these contexts. A greater understanding of 
endoglin’s function in TGF, BMP signaling, and TGF-independent mediated effects should be 
undertaken in order to explain the variety of phenotypic differences in these two distinct MSC 
populations.  
 The studies outlined in Chapter 2, where MSCs affected the differentiation of stimulated CD4+ T-
cells, are novel and thorough in their description of this phenomenon. However, there are further 
avenues through which the mechanism could be explored. All of these studies have generated data from 
observing changes in the T-cell portion of the co-culture. By the quantification of MSC-secreted factors 
that drive Th2-differentiation, such as IL-5 and IL-4, it could perhaps illuminate the mechanism by which 
MSCs influence differentiation.  To elucidate the role of CD105 in the secretion of these factors, a direct 
comparison of CD105+/- cells should be undertaken; wherein an effective siRNA-based CD105-
knockdown could be applied.149 Applying these methods to a CD105+ population would be interesting to 
determine if the MSCs maintained their distinct differentiation-influencing capacities. These studies 
would identify CD105-negativity as a primary factor for Th2 differentiation as regulated by MSCs, if this 
hypothesis is proven by future data.  
 Additionally, exploring the in vivo consequences of increased Th2 differentiation in an allogeneic 
setting would be a logical subsequent step for investigating this phenomenon.  Previously, our group has 
demonstrated that CD105- MSCs are more adept at preserving cardiac function than an unfractionated 
set of MSCs, when injected in areas of reperfused-ischemia. To determine if these cells are 
accomplishing functional preservation by increasing the number of Th2 cells in the immunologic milieu 
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after infarct, tissue-sections could be fluorescently stained with antibodies that detect Th2-specific 
markers. The cells with Th2-indicators could be quantified and compared in syngeneic and allogeneic 
settings, and with varying endoglin expression. This would correlate in vivo functional data with a 
potential mechanism that does not include direct transdifferentiation of the MSCs themselves. Instead, 
it would prove that the MSCs are serving as a therapeutic intermediate to help quell reperfusion-based 
tissue damage.  
 These experiments and the works of others have barely scratched the surface for the 
mechanism by which endoglin expression is regulated via HBO. While HBO was shown in clinical trials to 
be therapeutically beneficial for HSPC transplant patients, the role of CD105 has not been defined. In 
previous work, HSPCs have had visualized interactions with osteoclasts to explore the osteoclastic role in 
the BM-niche microenvironment.150 The application of this technique for exploratory assays using 
CD105+/- MSCs and HSPCs might give clarity as to their purposes in this setting. Using HBO to determine 
the part that MSC-regulation plays in the niche, and for the identification of other potential endoglin-
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